[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 612
1. Han X, Bueso-Ramos CE: Advances in the pathological diagnosis and biology of acute lymphoblastic leukemia. Ann Diagn Pathol; 2005 Aug;9(4):239-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An accurate diagnosis of acute lymphocytic leukemia requires careful examination of the morphology, immunophenotype, genetic features, clinical characteristics, and molecular findings.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Diagn Pathol. 2007 Feb;11(1):79
  • (PMID = 16084461.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 111
  •  go-up   go-down


2. Au WY, Wong KY, Wan TS, So JC, Srivastava G, Liang R: A unique case of B cell lymphoma relapsing as CD4/CD56 blastic neoplasm. Leuk Lymphoma; 2009 Jun;50(6):932-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A unique case of B cell lymphoma relapsing as CD4/CD56 blastic neoplasm.
  • A patient with history of B cell lymphoma treated with rituximab-based chemotherapy relapsed with a blastic CD4+/CD56+ neoplasm that was negative for CD20, CD79a and CD3.
  • The relapse morphology and immunophenotyping were unusual and plasmacytoid dendritic cell (PDC) tumor enters the differential diagnosis.
  • However, expressions of Oct-2 and CD10 in the relapse tumor were both more compatible with B cell than PDC lineage.
  • Molecular investigations showed clonal rearrangements for both immunoglobulin heavy chain (IgH) and T cell receptor (TCR) gamma chain gene by polymerase chain reaction (PCR).
  • Furthermore, a clonal relationship with the original B cell lymphoma was demonstrated for all PCR products.
  • Our case illustrated the potential pitfalls and ambiguity of lineage classification based on morphology and immunophenotyping alone, especially for rare and poorly defined entities.
  • [MeSH-major] Antigens, CD4 / analysis. Antigens, CD56 / analysis. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Aged, 80 and over. Antigens, CD20 / analysis. Base Sequence. Dendritic Cells / metabolism. Dendritic Cells / pathology. Diagnosis, Differential. Flow Cytometry. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains / genetics. Immunophenotyping. Karyotyping. Male. Molecular Sequence Data. Neoplasm Recurrence, Local. Neoplastic Stem Cells / metabolism. Neoplastic Stem Cells / pathology. Octamer Transcription Factor-2 / analysis. Polymerase Chain Reaction. Receptors, Antigen, T-Cell, gamma-delta / genetics. Sequence Homology, Nucleic Acid

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19504395.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD4; 0 / Antigens, CD56; 0 / Immunoglobulin Heavy Chains; 0 / Octamer Transcription Factor-2; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


3. Specchia G, Albano F, Anelli L, Zagaria A, Liso A, Pannunzio A, Archidiacono N, Liso V, Rocchi M: Molecular cytogenetic study of instability at 1q21 approximately q32 in adult acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2005 Jan 1;156(1):54-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present paper, we report a molecular cytogenetic study of 1q abnormalities associated with t(8;14)(q24;q32) in an adult common B acute lymphoblastic leukemia case with FAB-L2 morphology.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 1. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15588856.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Carbone A, Gloghini A: AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol; 2005 Sep;130(5):662-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The vast majority of these lymphomas are high-grade B-cell lymphomas: Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) with centroblastic (CB) features and DLBCL with immunoblastic (IBL) features;.
  • (2) unusual lymphomas occurring more specifically in HIV-positive patients and include two rare entities, namely 'primary effusion lymphoma' (PEL) and 'plasmablastic lymphoma' of the oral cavity.
  • (2) extracavitary and arise in nodal and/or extranodal sites; and (3) histologically, they usually display a PEL-like morphology and plasma cell-related phenotype.
  • [MeSH-major] HIV-1. Lymphoma, AIDS-Related. Lymphoma, Non-Hodgkin. Sarcoma, Kaposi


5. Ilgenfritz RB, Kayasut K, Le Tourneau A, Calendini OA, Ouafi L, Marzac C, Diebold J, Devez F, Ducruit V, Bouchet PE, Audouin J, Molina TJ: Correlation between molecular and histopathological diagnoses of B cell lymphomas in bone marrow biopsy and aspirates. J Clin Pathol; 2009 Apr;62(4):357-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between molecular and histopathological diagnoses of B cell lymphomas in bone marrow biopsy and aspirates.
  • AIMS: PCR has been shown previously to be the most sensitive technique to detect a clonal population in marrow aspirates (MAs), and the clinical standard for evaluation of bone marrow lymphoma involvement today is bone marrow trephine biopsy (BMTB).
  • The goal of this study was to compare morphological evaluation of B cell neoplasm in BMTB (histology and immunohistochemistry) and PCR analysis in MA, with both specimens obtained at the same time, in patients with a known molecular marker of the disease.
  • METHODS: This was a retrospective evaluation of 98 consecutive BMTB specimens from 60 patients with a known B-cell neoplasm and a previous PCR marker of the disease (BCL2 and/or IGH).
  • RESULTS: Considering the IGH PCR cases alone, a B cell clone was detected in 85% and 39% of the morphology (M) positive and negative groups, respectively.
  • Five M(+), IGH(-) cases were found, including two cases of follicular lymphoma (FL), one case of diffuse large B cell lymphoma, and two cases of mantle cell lymphoma.
  • All other cases had minimal lymphoma localisation.
  • On the other hand, the PCR study for BCL2 is more sensitive than morphology, without any false negative results in this series, suggesting that BCL2-MBR PCR on MA can be used as an alternative and more sensitive examination for disease evaluation, providing that there is careful analysis of data, adequate knowledge of PCR pitfalls and absence of other haematological disorders.
  • [MeSH-major] Bone Marrow Examination / methods. Lymphoma, B-Cell / diagnosis

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329714.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


6. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project: Molecular diagnosis of Burkitt's lymphoma. N Engl J Med; 2006 Jun 8;354(23):2431-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnosis of Burkitt's lymphoma.
  • BACKGROUND: The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma is crucial because these two types of lymphoma require different treatments.
  • We examined whether gene-expression profiling could reliably distinguish Burkitt's lymphoma from diffuse large-B-cell lymphoma.
  • METHODS: Tumor-biopsy specimens from 303 patients with aggressive lymphomas were profiled for gene expression and were also classified according to morphology, immunohistochemistry, and detection of the t(8;14) c-myc translocation.
  • RESULTS: A classifier based on gene expression correctly identified all 25 pathologically verified cases of classic Burkitt's lymphoma.
  • Burkitt's lymphoma was readily distinguished from diffuse large-B-cell lymphoma by the high level of expression of c-myc target genes, the expression of a subgroup of germinal-center B-cell genes, and the low level of expression of major-histocompatibility-complex class I genes and nuclear factor-kappaB target genes.
  • Eight specimens with a pathological diagnosis of diffuse large-B-cell lymphoma had the typical gene-expression profile of Burkitt's lymphoma, suggesting they represent cases of Burkitt's lymphoma that are difficult to diagnose by current methods.
  • Among 28 of the patients with a molecular diagnosis of Burkitt's lymphoma, the overall survival was superior among those who had received intensive chemotherapy regimens instead of lower-dose regimens.
  • CONCLUSIONS: Gene-expression profiling is an accurate, quantitative method for distinguishing Burkitt's lymphoma from diffuse large-B-cell lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / genetics. Gene Expression. Gene Expression Profiling. Lymphoma, B-Cell / genetics


7. Gupta V, Singh SM: Gender dimorphism of macrophage response to GMCSF and IL-4 for differentiation into dendritic cells. Am J Reprod Immunol; 2008 Jul;60(1):43-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROBLEM: We previously demonstrated the existence of gender dimorphism in a murine tumor model with respect to the growth of a spontaneous T-cell lymphoma designated as Dalton's lymphoma and several aspects of host-tumor interaction.
  • Although monocytes/macrophages of tumor-bearing hosts have been used to differentiate into macrophage-derived dendritic cells for various applications in the immunotherapy of cancer, it remains unclear if macrophages show a gender-dependent differential response to the signals of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) for differentiation to cells with dendritic cell morphology (MO-DC) and if these MO-DC have a gender-dependent differential therapeutic efficacy in inhibiting tumor growth.
  • METHOD OF STUDY: Peritoneal macrophage obtained from male and female mice were incubated in vitro for a period of 7 days in a medium containing GM-CSF (800 IU/mL) and IL-4 (500 IU/mL) followed by incubation for further 24 hr in medium alone or containing lipopolysaccharide (LPS; 10 ng/mL) to differentiate into cells with DC morphology (MO-DC).
  • CONCLUSION: To the best of our knowledge, this is the first report of its kind to demonstrate the existence of gender dimorphism in the antitumor and other accessory functions of macrophages differentiated in vitro into cells with DC morphology.
  • [MeSH-major] Cell Differentiation / physiology. Dendritic Cells / cytology. Interleukin-4 / pharmacology. Macrophages / cytology. Sex Characteristics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18593437.001).
  • [ISSN] 1046-7408
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Cytokines; 207137-56-2 / Interleukin-4; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


8. Singh MP, Sharma H, Singh SM: Prolactin promotes growth of a spontaneous T cell lymphoma: role of tumor and host derived cytokines. Cancer Invest; 2006 Oct;24(6):601-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolactin promotes growth of a spontaneous T cell lymphoma: role of tumor and host derived cytokines.
  • The present study was conducted to investigate the effect of prolactin (PRL) on the progressive growth of a T cell lymphoma.
  • Using a murine model of a transplantable T cell lymphoma, designated as the Dalton's lymphoma (DL) it is shown that in vivo administration of PRL to tumor bearing mice reduces the survival duration of tumor-bearing host due to an augmentation of tumor growth.
  • PRL-treated DL cells showed an increase in cell size along with a decrease in cells with apoptotic morphology.
  • The study is of novel significance as it demonstrates for the first time that PRL can promote growth of a T cell lymphoma involving host and tumor-derived tumor growth promoting cytokines.
  • [MeSH-major] Cell Proliferation / drug effects. Lymphoma, T-Cell / pathology. Prolactin / pharmacology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982465.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CAD trifunctional enzyme; 0 / Interleukin-1; 0 / Interleukin-2; 0 / Transforming Growth Factor beta; 81627-83-0 / Macrophage Colony-Stimulating Factor; 9002-62-4 / Prolactin; EC 2.1.3.2 / Aspartate Carbamoyltransferase; EC 3.4.22.- / Caspases; EC 3.5.2.3 / Dihydroorotase; EC 6.3.5.5 / Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing)
  •  go-up   go-down


9. Tierens AM, Holte H, Warsame A, Ikonomou IM, Wang J, Chan WC, Delabie J: Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type. Haematologica; 2010 Aug;95(8):1334-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type.
  • BACKGROUND: Multiparameter flow cytometry allows the detection of minor monoclonal B-cell populations.
  • Using this technique combined with morphology, we were struck by the presence of minor populations of small monoclonal B cells in bone marrows of patients with diffuse large B-cell lymphoma in routine diagnostic samples and performed a systematic retrospective study.
  • DESIGN AND METHODS: Bone marrows of 165 patients with primary diffuse large B-cell lymphoma without histological evidence of concurrent non-Hodgkin's lymphoma were studied by routine microscopy of trephines and smears, immunohistochemistry and multiparameter flow cytometry.
  • RESULTS: Diffuse large B-cell lymphoma infiltration in marrows was documented in 11 of 165 patients.
  • Of interest, only 3 of 119 patients with diffuse large B-cell lymphoma not otherwise specified, the largest subtype, showed marrow infiltration.
  • By contrast, flow cytometry revealed a minor monoclonal B-cell population in 24 of 165 patients, none of whom showed diffuse large B-cell lymphoma infiltration by morphology.
  • Moreover, 11 of 39 (28.2%) of patients with diffuse large B-cell lymphoma not otherwise specified of ABC subtype and only 3 of 80 (3.7%) with the GCB subtype showed these monoclonal small B cells (P=0.0002).
  • In addition 4 of 8 (50%), 4 of 15 (26.7%) and 2 of 3 (66.7%) patients with primary testicular, primary central nervous system and leg-type diffuse large B-cell lymphoma, respectively, showed monoclonal small B cells.
  • CONCLUSIONS: Bone marrow infiltration with diffuse large B-cell lymphoma in patients with diffuse large B-cell lymphoma not otherwise specified is rare at diagnosis.
  • By contrast, a high number of diffuse large B-cell lymphoma not otherwise specified of the ABC subtype but not of GCB subtype is associated with monoclonal small B cells in the marrow.
  • Whether these monoclonal small B cells are precursors of diffuse large B-cell lymphoma of the ABC type or arise in a common background that favors clonal B-cell expansion remains to be demonstrated.
  • [MeSH-major] B-Lymphocytes / pathology. Bone Marrow Cells / pathology. Germinal Center / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2337-42 [14630808.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):236-42 [1988571.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Am J Clin Pathol. 1994 Mar;101(3):305-11 [8135186.001]
  • [Cites] Leukemia. 1996 May;10(5):877-95 [8656686.001]
  • [Cites] Mod Pathol. 1999 Mar;12(3):272-8 [10102612.001]
  • [Cites] Blood. 2005 May 1;105(9):3671-8 [15308563.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):325-32 [16042682.001]
  • [Cites] Blood. 2006 Jan 1;107(1):190-6 [16150948.001]
  • [Cites] J Pathol. 2006 Oct;210(2):163-71 [16823896.001]
  • [Cites] N Engl J Med. 2008 Aug 7;359(6):575-83 [18687638.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5 [18765795.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] Blood. 2009 Jul 2;114(1):33-7 [19420353.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3889-96 [10572105.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3569-77 [11071656.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Blood. 2002 Jul 15;100(2):635-9 [12091358.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1460-9 [12145686.001]
  • [Cites] Lab Invest. 2003 Jan;83(1):107-14 [12533691.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Jul;54(1):10-8 [12827663.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Haematologica. 2003 Dec;88(12):1358-65 [14687988.001]
  • [Cites] Am J Clin Pathol. 1990 Jul;94(1):59-66 [2360564.001]
  • (PMID = 20145271.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Immunoglobulin Heavy Chains
  • [Other-IDs] NLM/ PMC2913082
  •  go-up   go-down


10. Kumar S, Rau AR, Naik R, Kini H, Mathai AM, Pai MR, Khadilkar UN: Bone marrow biopsy in non-Hodgkin lymphoma: a morphological study. Indian J Pathol Microbiol; 2009 Jul-Sep;52(3):332-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow biopsy in non-Hodgkin lymphoma: a morphological study.
  • CONTEXT: Bone marrow (BM) biopsy is an integral part of staging work-up for non-Hodgkin lymphoma (NHL).
  • AIMS: To study the characteristics of BM involvement in NHL with respect to incidence, histologic pattern and morphology of infiltration and its discordance with the histology of primary anatomic site.
  • RESULTS: BM biopsy showed involvement by lymphoma in 27 cases (55.10%).
  • The incidence of involvement was higher in T-cell lymphomas when compared with B-cell lymphomas and predominant pattern of involvement was mixed.
  • Diffuse large B-cell lymphomas had the lowest incidence in all the B-cell lymphomas.
  • A discordant histology between BM and primary anatomic site was found in 29.63% (8/27) of the cases, where it was seen more in follicular lymphomas and diffuse large B-cell lymphomas.
  • [MeSH-major] Bone Marrow / pathology. Bone Marrow Diseases / pathology. Lymphoma, B-Cell / complications. Lymphoma, T-Cell / complications


11. Traverse-Glehen A, Pittaluga S, Gaulard P, Sorbara L, Alonso MA, Raffeld M, Jaffe ES: Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol; 2005 Nov;29(11):1411-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.
  • In recent years, overlap in biologic and morphologic features has been identified between classic Hodgkin lymphoma (cHL) and B-cell non-Hodgkin lymphoma.
  • We undertook a study of "mediastinal gray zone lymphomas" (MGZL), with features transitional between cHL nodular sclerosis (NS) and primary mediastinal large B-cell lymphoma (MLBCL) to better understand the morphologic and immunophenotypic spectrum of such cases.
  • We also studied 6 cases of composite or synchronous lymphoma with two distinct components at the same time (cHL-NS and MLBCL) and 9 sequential cases with MLBCL and cHL-NS at different times.
  • Immunohistochemical studies focused on markers known to discriminate between cHL and MLBCL, including B-cell transcription factors.
  • Of the gray zone cases, 11 had morphology reminiscent of cHL-NS, but with unusual features, including a large number of mononuclear variants, diminished inflammatory background, absence of classic Hodgkin phenotype, and strong CD20 expression (11 of 11).
  • Ten cases had morphology of MLBCL, but with admixed Hodgkin/Reed-Sternberg and lacunar cells, absent (3 of 10) or weak (7 of 10) CD20 expression, and positivity for CD15 in 7 cases.
  • B-cell transcription factor expression in the gray zone cases more closely resembled MLBCL than cHL with expression of Pax5, Oct2, and BOB.1 in all but 1 case studied (14 of 15).
  • Two cases of sequential lymphoma showed rearrangements of the IgH gene of identical size: one in which MLBCL was the first diagnosis and one in which MLBCL was diagnosed at relapse, indicating clonal identity for the two components of cHL and MLBCL.
  • Further support for a relationship between MLBCL and cHL-NS is provided by composite and metachronous lymphomas in the same patient, as well as the existence of MGZL with transitional morphology and phenotype.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell / pathology. Mediastinal Neoplasms / pathology


12. Hayes D Jr: Nosocomial pulmonary Rhizopus diagnosed by bronchoalveolar lavage with cytology in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol; 2006 Jun;23(4):323-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The author presents a case that further describes the benefit of performing BAL fluid cytology to help identify fungal morphology characteristics in order to reach an expeditious diagnosis of Rhizopus species in a leukemia patient.
  • [MeSH-major] Lung Diseases, Parasitic / diagnosis. Mucormycosis / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Rhizopus / isolation & purification

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. TOBRAMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16621774.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Phosphatidylcholines; 0 / Phosphatidylglycerols; 0 / liposomal amphotericin B; 7XU7A7DROE / Amphotericin B; VZ8RRZ51VK / Tobramycin
  •  go-up   go-down


13. Al-Salam S, Al-Ashari M: Expression of Galectin-3, CD138, p16INK4a, and TTF-1 in mucinous bronchioloalveolar adenocarcinoma after Hodgkin lymphoma. Appl Immunohistochem Mol Morphol; 2009 Jul;17(4):351-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Galectin-3, CD138, p16INK4a, and TTF-1 in mucinous bronchioloalveolar adenocarcinoma after Hodgkin lymphoma.
  • Bronchioloalveolar carcinoma (BAC) is a subset of lung adenocarcinoma that has a distinct clinical presentation, tumor biology, response to therapy, and prognosis compared with other subtypes of non-small-cell lung carcinoma.
  • We describe a case of young female who received radiation therapy to the mediastinum and chemotherapy for Hodgkin lymphoma and now develops mucinous bronchioalveolar adenocarcinoma of the left lung which to the best of our knowledge has not been previously described after radiotherapy and chemotherapy for Hodgkin lymphoma.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18997617.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Galectin 3; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


14. Leong CF, Zainina S, Cheong SK: Congenital dyserythropoietic anaemia type II-like dysplastic anaemia preceding the development of non-Hodgkin lymphoma--a case report. Malays J Pathol; 2005 Jun;27(1):39-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital dyserythropoietic anaemia type II-like dysplastic anaemia preceding the development of non-Hodgkin lymphoma--a case report.
  • Anaemia is a frequent complication in patients with haematological malignancies and is caused by a variety of mechanisms including neoplastic cell infiltration into the bone marrow, haemolysis, nutritional deficiencies and defect in erythropoiesis or dysplastic anaemia as a result of the disease itself.
  • However, acquired dysplastic anaemia which mimic congenital dyserythropoietic anaemia (CDA) type II morphology in the bone marrow is very rare.
  • Bone marrow aspiration was done and showed congenital dyserythropoietic anaemia (CDA) type II-like morphology.
  • Biopsy of the lymph node confirmed the diagnosis of small lymphocytic lymphoma.
  • Staging with computed tomography and bone marrow aspirate revealed the infiltration of lymphoma cells into the marrow cavity consistent with the staging of IVB.
  • This case report illustrates that CDA type II-like dysplastic anaemia can preceed the development of lymphoma.
  • [MeSH-major] Anemia, Dyserythropoietic, Congenital / pathology. Lymphoma, Non-Hodgkin / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16676692.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


15. Uccella S, Placidi C, Marchet S, Cergnul M, Proserpio I, Chini C, Novario R, Pinotti G, Capella C: Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas: a single centre experience. Leuk Lymphoma; 2008 Jul;49(7):1321-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas: a single centre experience.
  • Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease.
  • The immunohistochemistry-based algorithms for the determination of the cell of origin of DLBCL have been proposed as a practical method to validate and surrogate results obtained by gene expression profiling.
  • The immunohistochemistry-based algorithms for the determination of the cell of origin of DLBCL were not associated with prognosis.
  • By contrast, Bcl-6 expression was associated with a longer lymphoma-free survival while immunoreactivities for MUM1 or Bcl-2 were not significantly related to patient outcome.
  • [MeSH-major] Germinal Center / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Predictive Value of Tests. Proto-Oncogene Proteins c-bcl-6 / analysis

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604721.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / interferon regulatory factor-4; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


16. Mayoral RJ, Pipkin ME, Pachkov M, van Nimwegen E, Rao A, Monticelli S: MicroRNA-221-222 regulate the cell cycle in mast cells. J Immunol; 2009 Jan 1;182(1):433-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA-221-222 regulate the cell cycle in mast cells.
  • Here, we have used mast cells as a model to investigate the role of miRNAs in differentiated innate immune cells and found that miR-221-222 are significantly up-regulated upon mast cell activation.
  • Overexpression of miR-221-222 in a model mast cell line perturbed cell morphology and cell cycle regulation without altering viability.
  • While in stimulated cells miR-221-222 partially counteracted expression of the cell-cycle inhibitor p27(kip1), we found that in the mouse alternative splicing results in two p27(kip1) mRNA isoforms that differ in their 3' untranslated region, only one of which is subject to miR-221-222 regulation.
  • Additionally, transgenic expression of miR-221-222 from bacterial artificial chromosome clones in embryonic stem cells dramatically reduced cell proliferation and severely impaired their accumulation.
  • Our study provides further insights on miR-221-222 transcriptional regulation as well as evidences that miR-221-222 regulate cell cycle checkpoints in mast cells in response to acute activation stimuli.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2745-54 [18417445.001]
  • [Cites] J Exp Med. 2008 Mar 17;205(3):611-24 [18299398.001]
  • [Cites] Science. 2008 Jun 20;320(5883):1643-7 [18566288.001]
  • [Cites] Nat Cell Biol. 2008 Jul;10(7):788-801 [18568019.001]
  • [Cites] Nature. 2008 Sep 4;455(7209):64-71 [18668037.001]
  • [Cites] Nature. 2008 Sep 4;455(7209):58-63 [18668040.001]
  • [Cites] Genome Res. 2000 Apr;10(4):577-86 [10779500.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):643-51 [12055628.001]
  • [Cites] Immunity. 2002 Jul;17(1):41-50 [12150890.001]
  • [Cites] Oncogene. 2002 Sep 26;21(43):6669-79 [12242665.001]
  • [Cites] Immunity. 2002 Nov;17(5):665-76 [12433372.001]
  • [Cites] Genes Dev. 2003 Sep 15;17(18):2205-32 [12975316.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] Nat Immunol. 2004 Aug;5(8):768-74 [15282556.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36210-8 [15229217.001]
  • [Cites] Genome Res. 2004 Oct;14(10A):1902-10 [15364901.001]
  • [Cites] EMBO J. 2004 Oct 13;23(20):4051-60 [15372072.001]
  • [Cites] Nature. 1994 Sep 15;371(6494):221-6 [8078582.001]
  • [Cites] Science. 1996 May 10;272(5263):892-5 [8629027.001]
  • [Cites] Annu Rev Immunol. 1997;15:707-47 [9143705.001]
  • [Cites] Blood. 1997 May 15;89(10):3636-43 [9160668.001]
  • [Cites] Oncogene. 1998 May 14;16(19):2549-56 [9627120.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5533-45 [9710637.001]
  • [Cites] Immunity. 1998 Dec;9(6):765-75 [9881967.001]
  • [Cites] Blood. 1999 May 15;93(10):3167-215 [10233871.001]
  • [Cites] J Exp Med. 2004 Nov 15;200(10):1257-66 [15545353.001]
  • [Cites] Nat Immunol. 2004 Dec;5(12):1251-9 [15516924.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):35-48 [15621779.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Nat Immunol. 2005 Feb;6(2):135-42 [15662442.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Genome Biol. 2005;6(8):R71 [16086853.001]
  • [Cites] Int Immunol. 2005 Nov;17(11):1513-24 [16199489.001]
  • [Cites] Cell. 2005 Dec 2;123(5):819-31 [16325577.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18081-6 [16330772.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • [Cites] Immunol Res. 2006;34(2):97-115 [16760571.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12481-6 [16885212.001]
  • [Cites] Cell. 2006 Sep 22;126(6):1203-17 [16990141.001]
  • [Cites] Immunobiology. 2006;211(10):815-20 [17113919.001]
  • [Cites] Nat Rev Immunol. 2007 Feb;7(2):105-17 [17259967.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):578-89 [17344418.001]
  • [Cites] Cell. 2007 Apr 6;129(1):147-61 [17382377.001]
  • [Cites] Science. 2007 Apr 27;316(5824):604-8 [17463289.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] J Biol Chem. 2007 Aug 10;282(32):23716-24 [17569667.001]
  • [Cites] EMBO J. 2007 Aug 8;26(15):3699-708 [17627278.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8699-707 [17875710.001]
  • [Cites] BMC Bioinformatics. 2007;8 Suppl 6:S4 [17903285.001]
  • [Cites] Cell. 2007 Oct 5;131(1):146-59 [17923094.001]
  • [Cites] Science. 2007 Dec 21;318(5858):1931-4 [18048652.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):43-50 [18066065.001]
  • [Cites] Nat Rev Genet. 2008 Feb;9(2):102-14 [18197166.001]
  • [Cites] Semin Cancer Biol. 2008 Apr;18(2):79-88 [18291671.001]
  • [Cites] Nat Rev Immunol. 2008 Jun;8(6):478-86 [18483499.001]
  • (PMID = 19109175.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F32 CA126247; United States / NCI NIH HHS / CA / CA126247-02; United States / NIAID NIH HHS / AI / R01 AI044432; United States / NIAID NIH HHS / AI / R01 AI044432-06; United States / NCI NIH HHS / CA / F32 CA126247-02; United States / NIAID NIH HHS / AI / AI070788-02; United States / NIAID NIH HHS / AI / AI070788; United States / NIAID NIH HHS / AI / R01 AI070788-02; United States / NCI NIH HHS / CA / F32 CA126247-01; United States / NIAID NIH HHS / AI / AI44432; United States / NIAID NIH HHS / AI / AI044432-06; United States / NIAID NIH HHS / AI / R01 AI070788
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Inhibitors; 0 / MIRN221 microRNA, human; 0 / MIRN222 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS79006; NLM/ PMC2610349
  •  go-up   go-down


17. Gouda I, Nada O, Ezzat S, Eldaly M, Loffredo C, Taylor C, Abdel-Hamid M: Immunohistochemical detection of hepatitis C virus (genotype 4) in B-cell NHL in an Egyptian population: correlation with serum HCV-RNA. Appl Immunohistochem Mol Morphol; 2010 Jan;18(1):29-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of hepatitis C virus (genotype 4) in B-cell NHL in an Egyptian population: correlation with serum HCV-RNA.
  • BACKGROUND AND AIM: Retrospective evaluation of hepatitis C virus (HCV) prevalence in lymphoma tissues has important applications in clarifying the contribution of viral factors to the pathogenesis.
  • Trials for detection of HCV at the cellular level in lymphoma tissues are, so far, minimal with unsatisfactory results.
  • We aimed to study the detection and localization of HCV in the tissues of B-cell non-Hodgkin lymphoma (NHL) patients.
  • DESIGN: We performed immunohistochemistry to detect the HCV nonstructural 3 protein in paraffin-embedded tissue specimens of B-cell NHL patients, in 39 serum HCV-RNA positive samples and 35 serum HCV-RNA negative samples as controls.
  • CONCLUSIONS: Immunohistochemical detection of HCV proteins in lymphoma tissues supports a potential role of viral replication in lymphomagenesis.
  • The low number of cases showing expression of viral proteins may represent a low viral load in lymphoid tissue and/or restriction of HCV protein expression to certain subtypes of B-cell NHL.
  • Immunohistochemistry can be used as a complementary tool for specific HCV detection in the paraffin-embedded material of lymphoma tissues not suitable for RNA analysis.

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis C (HCV).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lupus. 2000;9(2):83-91 [10787003.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Mar 15;21(6):653-62 [15771751.001]
  • [Cites] Hepatology. 2001 Jan;33(1):248-53 [11124843.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Am J Gastroenterol. 2002 Jul;97(7):1802-6 [12135039.001]
  • [Cites] Tumori. 2002 Sep-Oct;88(5):400-6 [12487559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4262-7 [14999097.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):252-7 [15224361.001]
  • [Cites] Int J Epidemiol. 2004 Oct;33(5):1034-9 [15155696.001]
  • [Cites] Nature. 1970 Dec 12;228(5276):1056-8 [4320657.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Jpn J Exp Med. 1990 Aug;60(4):215-22 [1963453.001]
  • [Cites] Hepatology. 1991 Aug;14(2):381-8 [1650328.001]
  • [Cites] Blood. 1993 Aug 1;82(3):872-6 [8393354.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1887-92 [7655017.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4638-45 [8977256.001]
  • [Cites] Blood. 1997 Apr 15;89(8):3066-8 [9108432.001]
  • [Cites] J Hum Virol. 1997 Nov-Dec;1(1):58-65 [10195232.001]
  • [Cites] Hepatology. 2005 Mar;41(3):652-9 [15723449.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1365-8 [16109616.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2078-85 [17119031.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1879-86 [17087949.001]
  • [Cites] J Vet Diagn Invest. 2007 Jan;19(1):35-42 [17459830.001]
  • [Cites] World J Gastroenterol. 2007 May 7;13(17):2467-78 [17552031.001]
  • [Cites] Egypt J Immunol. 2006;13(1):105-14 [17974155.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):630-3 [17935132.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):x-xii [18271007.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Lancet. 2000 Mar 11;355(9207):887-91 [10752705.001]
  • [Cites] Am J Clin Pathol. 2000 Mar;113(3):391-8 [10705820.001]
  • [Cites] Semin Liver Dis. 2000;20(1):85-102 [10895434.001]
  • (PMID = 19644357.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085888
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis C Antibodies; 0 / RNA, Viral
  • [Other-IDs] NLM/ NIHMS461675; NLM/ PMC3663591
  •  go-up   go-down


18. Mattii L, Azzarà A, Fazzi R, Carulli G, Chimenti M, Cecconi N, Galimberti S, Petrini M: Glycosylated or non-glycosylated G-CSF differently influence human granulocyte functions through RhoA. Leuk Res; 2005 Nov;29(11):1285-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this paper we show that in resting Filgrastim (non-glycosylated G-CSF)-pulsed cells, F-actin polymerization, membrane-linked RhoA and cell polarization are enhanced compared to those found in resting Lenograstim (glycosylated G-CSF)-cells.
  • Moreover, Filgrastim-mobilized cells, but not Lenograstim-mobilized cells, are unable to correctly respond to LPS stimulation, as demonstrated by minor further RhoA activation and cell elongation.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / pharmacology. Granulocytes / drug effects. Granulocytes / physiology. Lymphoma, Non-Hodgkin. rhoA GTP-Binding Protein / physiology
  • [MeSH-minor] Actins / chemistry. Actins / drug effects. Actins / physiology. Cell Count. Cell Polarity / drug effects. Cell Polarity / physiology. Filgrastim. Glycosylation. Humans. Neutrophils / cytology. Neutrophils / drug effects. Neutrophils / physiology. Peripheral Blood Stem Cell Transplantation. Recombinant Proteins / pharmacology. Remission Induction

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Filgrastim .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15916805.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Recombinant Proteins; 124671-05-2 / RHOA protein, human; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6WS4C399GB / lenograstim; EC 3.6.5.2 / rhoA GTP-Binding Protein; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


19. Higgins RA, Blankenship JE, Kinney MC: Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch Pathol Lab Med; 2008 Mar;132(3):441-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma.
  • CONTEXT: Beginning with the immunologic classifications of Lukes and Collins and Kiel and culminating in the Revised European-American Lymphoma and World Health Organization classifications, the diagnosis of lymphoid tumors relies heavily on the determination of cell lineage, maturation, and function, based on antigen expression in addition to morphology and clinical features.
  • OBJECTIVE: To provide guidance to the practicing pathologist in the appropriate selection of an antibody panel for the diagnosis of lymphoma based on morphology and relevant clinical data and to avoid pitfalls in the interpretation of immunohistochemical data.
  • [MeSH-major] Biomarkers, Tumor / analysis. Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis


20. Ardianto B, Sugimoto T, Kawano S, Kasagi S, Jauharoh SN, Kurimoto C, Tatsumi E, Morikawa K, Kumagai S, Hayashi Y: The HPB-AML-I cell line possesses the properties of mesenchymal stem cells. J Exp Clin Cancer Res; 2010;29:163
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The HPB-AML-I cell line possesses the properties of mesenchymal stem cells.
  • BACKGROUND: In spite of its establishment from the peripheral blood of a case with acute myeloid leukemia (AML)-M1, HPB-AML-I shows plastic adherence with spindle-like morphology.
  • Mixed lymphocyte culture demonstrated that CD3+ T-cell proliferation was suppressed in the presence of HPB-AML-I cells.
  • [MeSH-major] Cell Line, Tumor / cytology. Cell Line, Tumor / physiology. Mesenchymal Stromal Cells / cytology. Mesenchymal Stromal Cells / physiology. Neoplastic Stem Cells / cytology. Neoplastic Stem Cells / physiology
  • [MeSH-minor] Cell Differentiation / physiology. Cell Lineage. Humans

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Biol Int. 2006 Jun;30(6):495-9 [16731010.001]
  • [Cites] Leukemia. 2006 May;20(5):894-6 [16525488.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1505-7 [15902289.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(12):5183-95 [15923633.001]
  • [Cites] Mol Biol Cell. 2005 Mar;16(3):1491-9 [15647378.001]
  • [Cites] Science. 1996 Jul 26;273(5274):494-7 [8662537.001]
  • [Cites] Dev Biol. 1986 Sep;117(1):71-82 [3743900.001]
  • [Cites] Dev Biol. 1977 Oct 1;60(1):69-82 [198274.001]
  • [Cites] Lancet. 1971 Oct 30;2(7731):971-2 [4107917.001]
  • [Cites] J Gene Med. 2004 Aug;6(8):833-45 [15293342.001]
  • [Cites] Oncol Rep. 2004 Sep;12(3):501-8 [15289828.001]
  • [Cites] J Cell Physiol. 2003 Oct;197(1):42-52 [12942539.001]
  • [Cites] Scand J Immunol. 2003 Jan;57(1):11-20 [12542793.001]
  • [Cites] Leuk Res. 2006 Aug;30(8):993-1003 [16448696.001]
  • [Cites] Int Immunopharmacol. 2010 Dec;10(12):1496-500 [20619384.001]
  • [Cites] J Mol Med (Berl). 2010 Nov;88(11):1181-90 [20697686.001]
  • [Cites] J Cell Biochem. 2010 Oct 1;111(2):249-57 [20506559.001]
  • [Cites] Stem Cells. 2010 Aug;28(8):1446-55 [20597105.001]
  • [Cites] Cancer Res. 2010 Jun 1;70(11):4602-12 [20460510.001]
  • [Cites] J Mol Med (Berl). 2010 Mar;88(3):249-65 [20155409.001]
  • [Cites] Biomaterials. 2010 May;31(13):3564-71 [20153525.001]
  • [Cites] Neurosci Lett. 2010 Mar 19;472(2):94-8 [20117176.001]
  • [Cites] Leuk Res. 2006 Dec;30(12):1493-8 [16839603.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2436-43 [18045971.001]
  • [Cites] J Pathol. 2008 Oct;216(2):158-66 [18702172.001]
  • [Cites] Immunol Invest. 2008;37(7):726-39 [18821219.001]
  • [Cites] Tohoku J Exp Med. 2008 Oct;216(2):149-56 [18832797.001]
  • [Cites] Leuk Lymphoma. 2008 Nov;49(11):2187-95 [19021063.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):1776-81 [19208848.001]
  • [Cites] Leukemia. 2009 Apr;23(4):664-72 [19151777.001]
  • [Cites] In Vivo. 2009 Jan-Feb;23(1):21-7 [19368120.001]
  • [Cites] Arthritis Rheum. 2009 Aug;60(8):2325-32 [19644865.001]
  • [Cites] J Cell Physiol. 2010 Feb;222(2):268-77 [19847802.001]
  • [Cites] J Exp Med. 2009 Dec 21;206(13):3131-41 [19995953.001]
  • [Cites] J Cell Biochem. 2010 Feb 1;109(2):277-82 [19950205.001]
  • (PMID = 21144016.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3016278
  •  go-up   go-down


21. Simonenko VB, Frank GA, Zavalishina LE, Makanin MA, Ostrovskaia EIu, Beliaev LB, Dulin PA: [A rare case of large-cell gastric lymphoma in a patient with chronic lympholeucosis]. Klin Med (Mosk); 2006;84(12):62-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A rare case of large-cell gastric lymphoma in a patient with chronic lympholeucosis].
  • Chronic lympholeucosis (CLL) is a B-cell lymphoproliferative disease, the morphological substrate of which is a clone of lymphocytes similar in size and morphology to normal mature lymphocyte and similar in immunophenotype to B lymphocytes at late stages of differentiation.
  • The occurrence of large-cell lymphoma against the background of B-CLL is called Richter syndrome.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications. Stomach Neoplasms / complications


22. Soma LA, Craig FE, Swerdlow SH: The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum Pathol; 2006 Feb;37(2):152-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma.
  • Prognostication in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) based, in part, on ZAP-70 and CD38 expression, and to a lesser extent, on MUM1/IRF4 expression, is currently of great interest.
  • The more aggressive type of CLL/SLL is reportedly characterized by neoplastic cells that are more responsive to B-cell signaling with proliferation centers (PCs), a potentially important site of neoplastic cell stimulation.
  • They support the hypothesis that PCs are a site for B-cell receptor signaling, which helps explain reported site-dependent antigenic variation in CLL/SLL, and suggest that PC morphology may correlate with other biological features.
  • [MeSH-major] Biomarkers, Tumor / analysis. Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD38 / biosynthesis. Cell Proliferation. Female. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Interferon Regulatory Factors / biosynthesis. Male. Membrane Glycoproteins / biosynthesis. Prognosis. ZAP-70 Protein-Tyrosine Kinase / biosynthesis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426914.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interferon Regulatory Factors; 0 / Membrane Glycoproteins; 0 / interferon regulatory factor-4; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


23. Singh P, Alley TL, Wright SM, Kamdar S, Schott W, Wilpan RY, Mills KD, Graber JH: Global changes in processing of mRNA 3' untranslated regions characterize clinically distinct cancer subtypes. Cancer Res; 2009 Dec 15;69(24):9422-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using a mouse model of B-cell leukemia/lymphoma, we find that differences in transcript isoform abundance are likely due to both alternative polyadenylation (APA) and differential degradation.
  • Genes with elongated transcripts are overrepresented in ontology categories related to cell-cell adhesion and morphology.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2002 Jun 28;109(7):811-21 [12110179.001]
  • [Cites] Nat Genet. 2006 Jun;38(6):626-35 [16645617.001]
  • [Cites] Biochem Soc Trans. 2002 Nov;30(Pt 6):952-8 [12440953.001]
  • [Cites] Mol Cell. 2002 Dec;10(6):1379-90 [12504013.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(7):2463-75 [12640129.001]
  • [Cites] Trends Biochem Sci. 2003 Apr;28(4):182-8 [12713901.001]
  • [Cites] Nat Rev Genet. 2003 Aug;4(8):626-37 [12897774.001]
  • [Cites] Mol Cancer Res. 2003 Oct;1(12):882-91 [14573789.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2410-5 [14983023.001]
  • [Cites] Bioinformatics. 2004 Jun 12;20(9):1464-5 [14962934.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Nucleic Acids Res. 2000 Jan 15;28(2):520-6 [10606651.001]
  • [Cites] Nature. 2000 Apr 20;404(6780):897-900 [10786799.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] Nat Med. 2000 Jun;6(6):637-41 [10835679.001]
  • [Cites] Mol Cell. 2000 Jun;5(6):993-1002 [10911993.001]
  • [Cites] Cell. 2001 Mar 9;104(5):743-53 [11257228.001]
  • [Cites] Trends Genet. 2002 Mar;18(3):150-7 [11858839.001]
  • [Cites] Biotechniques. 2004 Aug;37(2):173-5, 177 [15335204.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] Biol Cell. 2004 Sep;96(7):479-98 [15380615.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • [Cites] Oncogene. 1994 Jul;9(7):1925-9 [8208539.001]
  • [Cites] Mol Cell Biol. 1995 Nov;15(11):6420-9 [7565794.001]
  • [Cites] Genes Dev. 1995 Nov 1;9(21):2672-83 [7590244.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11095-100 [9736695.001]
  • [Cites] Science. 1999 Sep 3;285(5433):1576-9 [10477523.001]
  • [Cites] Int J Hematol. 2004 Dec;80(5):389-94 [15646648.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):382-90 [15778709.001]
  • [Cites] Genes Dev. 2005 May 15;19(10):1227-37 [15905410.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6296-305 [16155012.001]
  • [Cites] Bioinformatics. 2006 Jun 15;22(12):1540-2 [16595560.001]
  • [Cites] Methods Enzymol. 2006;411:352-69 [16939800.001]
  • [Cites] Adv Exp Med Biol. 2007;593:74-85 [17265718.001]
  • [Cites] Cell Oncol. 2007;29(1):1-17 [17429137.001]
  • [Cites] Nucleic Acids Res. 2007 Jul;35(Web Server issue):W259-64 [17485471.001]
  • [Cites] BMC Bioinformatics. 2007;8:273 [17663764.001]
  • [Cites] Oncogene. 2007 Sep 6;26(41):6010-20 [17384673.001]
  • [Cites] Nat Genet. 2008 Feb;40(2):225-31 [18193047.001]
  • [Cites] Nucleic Acids Res. 2008 Apr;36(6):1792-804 [18252771.001]
  • [Cites] Science. 2008 Jun 20;320(5883):1643-7 [18566288.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1440-6 [18185523.001]
  • [Cites] Nature. 2008 Nov 27;456(7221):470-6 [18978772.001]
  • [Cites] Cell. 2009 Aug 21;138(4):673-84 [19703394.001]
  • [Cites] PLoS One. 2009;4(10):e7479 [19834616.001]
  • [Cites] Gene. 2006 Feb 1;366(2):325-34 [16316725.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] J Exp Med. 2002 Aug 19;196(4):469-80 [12186839.001]
  • (PMID = 19934316.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01GM072706; United States / NCI NIH HHS / CA / P30 CA034196; United States / NCI NIH HHS / CA / R01CA115665; United States / NCI NIH HHS / CA / R01 CA115665; United States / NCI NIH HHS / CA / 2P30CA034196; United States / NIGMS NIH HHS / GM / GM072706-04; United States / NIGMS NIH HHS / GM / R01 GM072706-04; United States / NIGMS NIH HHS / GM / R01 GM072706
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / MicroRNAs; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS153990; NLM/ PMC2794997
  •  go-up   go-down


24. Shiozawa E, Takimoto M, Makino R, Adachi D, Saito B, Yamochi-Onizuka T, Yamochi T, Shimozuma J, Maeda T, Kohno Y, Kawakami K, Nakamaki T, Tomoyasu S, Shiokawa A, Ota H: Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group. Leuk Res; 2006 Jul;30(7):859-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group.
  • PURPOSE: The aim of the study was to analyze the methylation status of the promoter regions of p15 and p16 and to assess the prognostic significance of promoter hypermethylation in diffuse large B-cell lymphoma (DLBCL).
  • EXPERIMENTAL DESIGN: DLBCL was diagnosed by morphology and immunohistochemical analysis according to the World Health Organization (WHO) classification.
  • [MeSH-major] Biomarkers, Tumor / genetics. CpG Islands. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Methylation. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406514.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


25. Liu A, Sugisaki Y, Hosone M, Namimatsu S, Maeda S, Naito Z, Ghazizadeh M: CD30-positive diffuse large B-cell lymphoma with microvillous features: so-called microvillous lymphoma. J Clin Pathol; 2009 Sep;62(9):840-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30-positive diffuse large B-cell lymphoma with microvillous features: so-called microvillous lymphoma.
  • A case of CD30-positive microvillous lymphoma (MVL) in an 87-year-old man who was encountered generalised lymphadenopathy is presented.
  • Histopathologically, the tumour showed a morphological mimic of anaplastic large cell lymphoma (ALCL) with sinusoidal growth pattern.
  • In conclusion, CD30-positive MVLs are indistinguishable from ALCLs that have ultrastructural microvillous projections by morphology alone.
  • The results of a panel of three markers (CD10(-), Bcl-6(+) and MUM1(+)) suggested that the present case of CD30-positive MVLs has an activated non-germinal centre B-cell origin.
  • [MeSH-major] Antigens, CD30 / analysis. Lymphoma, Large B-Cell, Diffuse / ultrastructure
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Lymphoma, Large-Cell, Anaplastic / diagnosis. Male. Microscopy, Electron. Microvilli / ultrastructure

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126565.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor
  •  go-up   go-down


26. Bäsecke J, Schwieger M, Griesinger F, Schiedlmeier B, Wulf G, Trümper L, Stocking C: AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiation. Leuk Lymphoma; 2005 Feb;46(2):265-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies to delineate the mechanism by which AML1-ETO induces leukemia have primarily relied on transformed human cell lines or murine model systems.
  • AML1-ETO expressing cells were expandable for up to 12 weeks and retained an immature morphology.
  • AML1/ETO-expressing cells also contributed to myeloid (CD15, CD33), B-lymphoid (CD20), NK-cell (CD56) and erythroid (GPA) lineages in xenografted NOD/SCID mice.
  • Although able to engraft all major lineages, AML1/ETO transplanted cells were primarily found in less differentiated fractions as measured by cell surface markers CD34 and CD38.
  • [MeSH-major] Cell Differentiation. Hematopoietic Stem Cells / cytology. Oncogene Proteins, Fusion / physiology. Transcription Factors / physiology
  • [MeSH-minor] Animals. Cell Lineage. Cell Proliferation. Cells, Cultured. Core Binding Factor Alpha 2 Subunit. Hematopoietic Stem Cell Transplantation. Humans. Leukemia / etiology. Mice. Mice, Inbred NOD. Mice, SCID. Transfection. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621811.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors
  •  go-up   go-down


27. Mocanu L, Cîmpean AM, Raica M: Expression of cytokeratin MNF116 and vimentin in pleural serous effusions. Rom J Morphol Embryol; 2007;48(3):291-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Antibodies / metabolism. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Eosine Yellowish-(YS). Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Melanoma / diagnosis. Melanoma / metabolism. Melanoma / pathology. Methylene Blue. Pleural Neoplasms / diagnosis. Pleural Neoplasms / secondary

  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914498.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antibodies; 0 / May-Grunwald Giemsa; 0 / Vimentin; 0 / cytokeratin MNF116, human; 68238-35-7 / Keratins; T42P99266K / Methylene Blue; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


28. Lee PS, Beneck D, Weisberger J, Gorczyca W: Coexpression of CD43 by benign B cells in the terminal ileum. Appl Immunohistochem Mol Morphol; 2005 Jun;13(2):138-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of CD43 by B cells is often used as a diagnostic criterion in favor of a B-cell lymphoproliferative disorder, including small lymphocytic lymphoma/chronic lymphocytic leukemia, mantle cell lymphoma, Burkitt lymphoma, precursor B-lymphoblastic lymphoma, and a subset of marginal zone B-cell lymphomas.
  • The presence of CD43 coexpression in B-cell populations of the terminal ileum, including those of Peyer's patches, should not be used as a diagnostic parameter to differentiate extranodal marginal zone B-cell lymphoma of MALT type from reactive processes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894925.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD43; 0 / Sialoglycoproteins; 0 / UN1 sialoglycoprotein, human
  •  go-up   go-down


29. Nagai K, Jinnai I, Hata T, Usui T, Sasaki D, Tsukasaki K, Sugahara K, Hishikawa Y, Yamada Y, Tanaka Y, Koji T, Mano H, Kamihira S, Tomonaga M: Adhesion-dependent growth of primary adult T cell leukemia cells with down-regulation of HTLV-I p40Tax protein: a novel in vitro model of the growth of acute ATL cells. Int J Hematol; 2008 Dec;88(5):551-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adhesion-dependent growth of primary adult T cell leukemia cells with down-regulation of HTLV-I p40Tax protein: a novel in vitro model of the growth of acute ATL cells.
  • In order to better understand the biology of adult T cell leukemia (ATL), we aimed to establish a novel method, which allows the primary growth of ATL cells using a co-culture system with murine bone marrow-derived stromal cells, MS-5.
  • In clinical samples, eight of ten (80.0%) cases of acute or lymphoma type ATL cells formed CAs.
  • The morphology, immunophenotyping, and DNA analysis indicated that cells composing CA were compatible with ATL cells, and clonally identical to primary CD4-positive ATL cells.
  • By microarray analysis, several genes which coded products involved in cell-cell interaction, and cellular survival and proliferation, were differentially expressed in ATL cells composing CA compared with primary samples.
  • [MeSH-major] Cell Proliferation. Down-Regulation. Gene Expression Regulation, Leukemic. Gene Products, tax / biosynthesis. Human T-lymphotropic virus 1. Leukemia-Lymphoma, Adult T-Cell / metabolism. Models, Biological
  • [MeSH-minor] Acute Disease. Animals. Cell Adhesion. Cell Line. Cell Survival. Coculture Techniques. Gene Expression Profiling. Humans. Interleukin-2 / pharmacology. Mice. Oligonucleotide Array Sequence Analysis. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 Feb 22;26(8):1245-55 [16909099.001]
  • [Cites] J Exp Med. 1996 Nov 1;184(5):1987-97 [8920885.001]
  • [Cites] Hematol Oncol. 1996 Jun;14(2):91-100 [8876638.001]
  • [Cites] J Clin Invest. 1985 Aug;76(2):446-53 [2993359.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Apr;81(8):2534-7 [6326131.001]
  • [Cites] Mol Cancer. 2006 Jun 19;5:25 [16784539.001]
  • [Cites] Clin Lab Haematol. 2003 Apr;25(2):111-7 [12641615.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(14):5620-4 [2787512.001]
  • [Cites] Leuk Res. 1993 Feb;17(2):157-66 [8429692.001]
  • [Cites] J Histochem Cytochem. 1981 Jun;29(6):775 [7252134.001]
  • [Cites] Annu Rev Immunol. 2001;19:475-96 [11244044.001]
  • [Cites] Retrovirology. 2008 Apr 22;5:34 [18426605.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Clin Exp Immunol. 2000 Apr;120(1):113-24 [10759772.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1631-8 [17502456.001]
  • [Cites] Immunity. 2006 Dec;25(6):989-1001 [17112751.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):720-5 [16407133.001]
  • [Cites] Immunol Cell Biol. 2003 Jun;81(3):171-5 [12752680.001]
  • [Cites] Blood. 2006 Dec 15;108(13):3979-82 [16917009.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Mar;288(3):C494-506 [15692148.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1204-13 [15471956.001]
  • [Cites] Blood. 1987 Aug;70(2):432-6 [2886161.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Feb 3;231(1):183-6 [9070245.001]
  • [Cites] AIDS Res Hum Retroviruses. 1992 Feb;8(2):227-35 [1371693.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3650-4 [10910081.001]
  • [Cites] Leukemia. 1994 Jul;8(7):1095-104 [8035601.001]
  • [Cites] Rev Med Virol. 2007 Sep-Oct;17 (5):301-11 [17621367.001]
  • [Cites] J Virol. 2003 May;77(9):5286-94 [12692230.001]
  • [Cites] J Exp Med. 1993 Mar 1;177(3):741-50 [8094736.001]
  • [Cites] Exp Hematol. 1989 Feb;17(2):145-53 [2783573.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3618-22 [6304725.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Dec;21(6):1007-34, vii-viii [17996586.001]
  • [Cites] Leuk Res. 1991;15(7):619-25 [1861543.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2951-8 [9108415.001]
  • [Cites] Int J Oncol. 1996 Oct;9(4):619-24 [21541560.001]
  • [Cites] J Virol. 2002 Dec;76(24):12813-22 [12438606.001]
  • [Cites] Leukemia. 2001 Apr;15(4):590-4 [11368361.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(22):8252-66 [16966377.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Blood. 1998 Feb 15;91(4):1263-71 [9454756.001]
  • [Cites] Intern Med. 1995 Oct;34(10):947-52 [8563094.001]
  • [Cites] Leukemia. 1999 Feb;13(2):215-21 [10025895.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3365-9 [16585154.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):17-23 [15652746.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):319-24 [10652420.001]
  • [Cites] Leukemia. 1992 May;6(5):452-8 [1375698.001]
  • [Cites] Nat Immunol. 2007 Oct;8(10):1076-85 [17721537.001]
  • [Cites] Leukemia. 1996 May;10(5):803-12 [8656675.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2350-7 [7662981.001]
  • [Cites] Mol Cell. 2003 Jan;11(1):113-26 [12535526.001]
  • [Cites] Int J Cancer. 1986 Jan 15;37(1):35-42 [3000953.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1063-71 [10190897.001]
  • [Cites] Leuk Lymphoma. 1995 Jan;16(3-4):319-27 [7719239.001]
  • [Cites] Blood. 1993 Jun 1;81(11):2916-24 [7684620.001]
  • [Cites] J Immunol. 1999 Dec 1;163(11):6209-16 [10570313.001]
  • [Cites] Int J Hematol. 2007 Aug;86(2):101-6 [17875521.001]
  • (PMID = 19043810.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / IL2 protein, human; 0 / Interleukin-2; 0 / tax protein, Human T-lymphotrophic virus 1
  •  go-up   go-down


30. Smock KJ, Yaish HM, Cairo MS, Lones MA, Willmore-Payne C, Perkins SL: Mantle cell lymphoma presenting with unusual morphology in an adolescent female: a case report and review of the literature. Pediatr Dev Pathol; 2007 Sep-Oct;10(5):403-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma presenting with unusual morphology in an adolescent female: a case report and review of the literature.
  • We report the case of an 18-year-old female initially diagnosed with CD5-negative diffuse large B-cell lymphoma in an inguinal lymph node in 1999 who subsequently relapsed with classic-morphology mantle cell lymphoma with involvement of the bone marrow, gastrointestinal tract, and spleen in 2004.
  • Both the 1999 and 2004 lesions were retrospectively positive for Cyclin D1 by immunohistochemistry and positive for t(11:14)(q13;q32) by fluorescence in situ hybridization, and both lesions had identical B-cell receptor gene rearrangements by polymerase chain reaction.
  • This case of a CD5-negative large cell or pleomorphic blastoid variant of mantle cell lymphoma arising in an 18-year-old represents a very early incidence for this type of lymphoma, which is usually not seen in younger patients.
  • [MeSH-major] Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / metabolism. Lymphoma, Mantle-Cell / pathology. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols. Cyclin D1 / biosynthesis. Diagnosis, Differential. Female. Flow Cytometry. Gene Rearrangement, B-Lymphocyte. Humans. In Situ Hybridization, Fluorescence. Lymphoma, Large B-Cell, Diffuse / pathology. Translocation, Genetic

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929987.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 136601-57-5 / Cyclin D1
  •  go-up   go-down


31. Sun XF, Zhen ZJ, Xia Y, Yang QY, Wang ZH, Ling JY: [The clinical features of B cell lymphoblastic lymphoma and outcomes after BFM-90 regimen therapy]. Zhonghua Xue Ye Xue Za Zhi; 2006 Oct;27(10):649-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical features of B cell lymphoblastic lymphoma and outcomes after BFM-90 regimen therapy].
  • OBJECTIVE: To analyse the clinical features of patients with B cell lymphoblastic lymphoma(BCLL) and the outcomes after modified BFM-90 protocol therapy.
  • METHODS: The clinical features of 14 patients with BCLL were analysed, and compared with that of T cell lymphoblastic lymphoma in the same period.
  • RESULTS: The 14 patients were aged 3 to 18 and diagnosed as BCLL by morphology and immunohistology.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343193.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


32. Kremer M, Ott G, Nathrath M, Specht K, Stecker K, Alexiou C, Quintanilla-Martinez L, Fend F: Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. J Pathol; 2005 Jan;205(1):92-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary extramedullary plasmacytomas are infrequent, typically solitary, plasma cell neoplasms that generally pursue an indolent clinical course but may, rarely, convert to multiple myeloma.
  • Nine patients developed local relapse and one patient's tumour evolved into a B-cell non-Hodgkin's lymphoma.
  • In comparison to extramedullary multiple myeloma, extramedullary plasmacytoma showed a more mature morphology and lower proliferation indices (p = 0.008).


33. Belloni-Fortina A, Montesco MC, Piaserico S, Bordignon M, Tona F, Feltrin G, Alaibac M: Primary cutaneous CD30+ anaplastic large cell lymphoma in a heart transplant patient: case report and literature review. Acta Derm Venereol; 2009;89(1):74-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD30+ anaplastic large cell lymphoma in a heart transplant patient: case report and literature review.
  • Most cases are of B-cell phenotype and are associated with Epstein-Barr virus infection.
  • Post-transplant lymphoproliferative disorders presenting clinically in the skin are rare and usually of B-cell phenotype.
  • Only rare cases of cutaneous T-cell post-transplant lymphoproliferative disorder have been reported previously, mostly mycosis fungoides type.
  • We describe here a rare primary cutaneous T-cell lymphoma CD30+ arising in a heart transplant patient who had a nodule on the right leg, several years after heart transplantation.
  • The morphology and immunohistochemical findings were consistent with a CD30+ anaplastic large cell lymphoma with a T-cell phenotype.
  • In conclusion, the diagnosis of a CD30+ anaplastic large cell lymphoma in transplant recipients does not imply aggressive clinical behaviour by the lymphoma.
  • [MeSH-major] Antigens, CD30 / analysis. Heart Transplantation. Lymphoma, T-Cell, Cutaneous / etiology. Skin Neoplasms / etiology


34. He H, Yang X, Davidson AJ, Wu D, Marshall FF, Chung LW, Zhau HE, Wang R: Progressive epithelial to mesenchymal transitions in ARCaP E prostate cancer cells during xenograft tumor formation and metastasis. Prostate; 2010 Apr 1;70(5):518-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer cells with stromal-like morphology were isolated and examined for EMT-like changes.
  • RESULTS: EMT-like morphologic and expression changes were detected after one round of in vivo tumor formation.
  • Importantly, when recovered tumor cells were used in second round xenograft tumor formation, a large fraction of ARCaP(E) cells showed drastic EMT-like changes, with markedly enlarged cell size and divergent cell shapes similar to those of mesenchymal stromal cells.
  • The morphologic change was accompanied by increased growth and metastasis, as tumor incidence increased while red fluorescent tumor cells could be detected from circulating blood, bone marrow, peritoneal ascites, and lung of the tumor-bearing mice.
  • The EMT appeared permanent since the newly acquired morphology was sustained after continuous passages.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15152-7 [8986779.001]
  • [Cites] Investig Urol (Berl). 1994;5:24-7 [7536522.001]
  • [Cites] Br J Cancer. 1997;76(9):1134-8 [9365160.001]
  • [Cites] Mutat Res. 1998 May 25;400(1-2):439-46 [9685702.001]
  • [Cites] Urology. 1999 Apr;53(4):707-13 [10197845.001]
  • [Cites] J Urol. 2005 Jan;173(1):10-20 [15592017.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8319-26 [16951136.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2479-88 [18381457.001]
  • [Cites] Clin Exp Metastasis. 2008;25(6):601-10 [18535913.001]
  • [Cites] Cell Res. 2008 Aug;18(8):858-70 [18645583.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9996-10003 [19047182.001]
  • [Cites] Prostate. 2006 Nov 1;66(15):1664-73 [16902972.001]
  • [Cites] Dev Cell. 2006 Oct;11(4):434-6 [17011482.001]
  • [Cites] Clin Genitourin Cancer. 2006 Sep;5(2):162-70 [17026806.001]
  • [Cites] Oncogene. 2007 Aug 2;26(35):5070-7 [17310988.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):374-83 [17680632.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):169-84 [11237532.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2001 Mar;37(3):127-40 [11370803.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):506-21 [12492493.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Aug;4(8):657-65 [12923528.001]
  • [Cites] Cancer Metastasis Rev. 1984;3(1):25-42 [6370418.001]
  • [Cites] Invasion Metastasis. 1982;2(3):137-76 [6765249.001]
  • [Cites] Biochim Biophys Acta. 1984;738(3):103-23 [6394045.001]
  • [Cites] Pathol Res Pract. 1987 Oct;182(5):617-26 [2446293.001]
  • [Cites] Cancer Metastasis Rev. 1990 Jul;9(1):1-20 [2208565.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5104-9 [1516067.001]
  • [Cites] Leuk Lymphoma. 1992 Sep;8(1-2):15-22 [1493467.001]
  • [Cites] Cancer Metastasis Rev. 1993 Mar;12(1):29-37 [8448824.001]
  • [Cites] Cancer Res. 1993 Aug 1;53(15):3585-90 [8339265.001]
  • [Cites] Urol Res. 1993;21(5):359-62 [7506464.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3929-33 [7518346.001]
  • [Cites] In Vivo. 1994 Jan-Feb;8(1):145-54 [8054504.001]
  • [Cites] J Cell Biochem Suppl. 1994;19:208-16 [7529853.001]
  • [Cites] Int Rev Cytol. 1998;177:1-56 [9378615.001]
  • (PMID = 19918799.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA122602; United States / NCI NIH HHS / CA / CA98912-02; United States / NCI NIH HHS / CA / R21CA112330; United States / NCI NIH HHS / CA / P20 CA132388; United States / NCI NIH HHS / CA / P01 CA098912; United States / NCI NIH HHS / CA / CA13289; United States / NCI NIH HHS / PC / PC040578; United States / NCI NIH HHS / CA / R21 CA112330; United States / NCI NIH HHS / CA / CA132388
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS323687; NLM/ PMC3180894
  •  go-up   go-down


35. Nigro M, Piscioli I, Franceschetti I, Barberini F, Lupattelli L, Scialpi M: Simultaneous occurrence of renal oncocytoma and B small cell lymphoma in the same kidney: report of two cases. Urol Int; 2009;83(2):242-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous occurrence of renal oncocytoma and B small cell lymphoma in the same kidney: report of two cases.
  • Two cases of simultaneous occurrence of oncocytoma (OC) associated with small B-cell lymphoma in the same kidney were investigated.
  • Diagnosis of OC was performed on the specimen by morphology, immunohistochemistry and electron microscopy.
  • The occurrence of OC and non-Hodgkin lymphoma in the same kidney has never been reported.
  • These case reports outline that computerized tomography is a sensitive method in the staging of lymphoma.
  • [MeSH-major] Adenoma, Oxyphilic. Kidney Neoplasms. Lymphoma, B-Cell. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 S. Karger AG, Basel.
  • (PMID = 19752626.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


36. Stevens JB, Abdallah BY, Regan SM, Liu G, Bremer SW, Ye CJ, Heng HH: Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation. Mol Cytogenet; 2010;3:20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation.
  • Mitotic cell death is an important form of cell death, particularly in cancer.
  • Chromosome fragmentation is a major form of mitotic cell death which is identifiable during common cytogenetic analysis by its unique phenotype of progressively degraded chromosomes.
  • This morphology however, can appear similar to the morphology of premature chromosome condensation (PCC) and thus, PCC has been at times confused with chromosome fragmentation.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20959006.001).
  • [ISSN] 1755-8166
  • [Journal-full-title] Molecular cytogenetics
  • [ISO-abbreviation] Mol Cytogenet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2974731
  •  go-up   go-down


37. Longerich T, Schirmacher P, Dienes HP, Stein H, Loddenkemper C: [Malignant lymphomas of the liver: new diagnostic algorithms]. Pathologe; 2006 Jul;27(4):263-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphomas involving the liver include, with decreasing frequency, diffuse large B-cell lymphoma, small lymphocytic lymphoma, Hodgkin's lymphoma, peripheral T-cell lymphoma, follicular lymphoma and extranodal marginal zone B-cell lymphoma.
  • Many B-cell lymphomas in the liver reveal a characteristic infiltration pattern allowing a rapid and cost-effective diagnosis based on focused immunohistochemical analyses.
  • In contrast, most T-cell lymphomas show a more diverse morphology, which is sometimes difficult to differentiate from a reactive condition.
  • The differential diagnosis includes hepatitis and inflammatory bile duct diseases, undifferentiated carcinoma, inflammatory myofibroblastic tumor as well as histiocytic and dendritic cell neoplasms.
  • [MeSH-major] Liver Neoplasms / pathology. Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 1998 Apr;29(3-4):293-9 [9684927.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2078-9 [14627800.001]
  • [Cites] Hematol J. 2004;5(6):530-3 [15570298.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):716-9 [10420230.001]
  • [Cites] Arch Pathol Lab Med. 1986 Jun;110(6):553-5 [3010899.001]
  • [Cites] Clin Radiol. 2001 Apr;56(4):295-301 [11286581.001]
  • [Cites] Pathol Int. 2004 Nov;54(11):830-6 [15533225.001]
  • [Cites] Blood. 1996 May 15;87(10):4296-301 [8639788.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1669-73 [10364042.001]
  • [Cites] Histopathology. 1995 Apr;26(4):311-21 [7607619.001]
  • [Cites] Dig Dis Sci. 1992 Jul;37(7):1105-9 [1618060.001]
  • [Cites] Cancer. 1985 Dec 15;56(12):2902-10 [3840404.001]
  • [Cites] J Clin Pathol. 1990 Dec;43(12):1007-13 [2266172.001]
  • [Cites] Acta Oncol. 1999;38(5):655-8 [10427957.001]
  • [Cites] J Hepatol. 1992 Jul;15(3):382-6 [1332999.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2639-46 [8453587.001]
  • [Cites] J Clin Gastroenterol. 1990 Aug;12(4):441-6 [2204655.001]
  • [Cites] Hepatology. 2003 Apr;37(4):781-7 [12668970.001]
  • [Cites] Eur J Surg. 1999 Aug;165(8):725-9 [10494635.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):285-96 [11224598.001]
  • [Cites] Clin Lab Haematol. 2003 Jun;25(3):185-6 [12755796.001]
  • [Cites] Ann Diagn Pathol. 1998 Dec;2(6):363-9 [9930573.001]
  • [Cites] Australas Radiol. 1999 Feb;43(1):98-101 [10901880.001]
  • [Cites] Histopathology. 1999 Oct;35(4):345-54 [10564389.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):135-8 [9149743.001]
  • [Cites] Med Pediatr Oncol. 1997 May;28(5):370-2 [9121404.001]
  • [Cites] Tokai J Exp Clin Med. 1991 Oct;16(3-4):171-3 [1811350.001]
  • [Cites] Eur J Haematol. 2005 May;74(5):445-7 [15813921.001]
  • [Cites] Can J Gastroenterol. 1997 Jan-Feb;11(1):77-81 [9113804.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4265-74 [8943863.001]
  • [Cites] Cancer. 1974 Mar;33(3):657-74 [4592903.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1710-3 [10430328.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Mar;53(3):199-207 [15718146.001]
  • [Cites] Hepatology. 1991 May;13(5):870-5 [2029991.001]
  • [Cites] Cancer. 1983 Dec 15;52(12):2285-8 [6640500.001]
  • [Cites] Leukemia. 1996 Feb;10(2):351-5 [8637247.001]
  • [Cites] Semin Liver Dis. 1987 Aug;7(3):257-68 [3317862.001]
  • [Cites] Virchows Arch. 2003 Feb;442(2):136-40 [12596064.001]
  • [Cites] J Gastroenterol. 2002;37(2):129-32 [11871764.001]
  • [Cites] Gastroenterology. 1975 Jan;68(1):105-12 [1054319.001]
  • [Cites] Am J Surg Pathol. 1993 Nov;17(11):1182-6 [8214264.001]
  • [Cites] Acta Pathol Jpn. 1991 Nov;41(11):829-33 [1785343.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(2):157-64 [9745082.001]
  • [Cites] Pathologe. 2000 Mar;21(2):147-61 [10840820.001]
  • [Cites] Pathol Res Pract. 1998;194(11):781-9 [9842637.001]
  • [Cites] Rinsho Ketsueki. 1990 Nov;31(11):1878-83 [2287076.001]
  • [Cites] J Rheumatol. 1989 Dec;16(12):1584-8 [2696791.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):604-8 [10747320.001]
  • [Cites] Cancer. 1996 Nov 1;78(9):2011-9 [8909324.001]
  • [Cites] Am J Clin Pathol. 2002 Oct;118(4):574-81 [12375645.001]
  • [Cites] Transplant Proc. 1995 Apr;27(2):1781-2 [7725502.001]
  • [Cites] Diagn Cytopathol. 1996 Mar;14(2):191-3 [8964182.001]
  • [Cites] Hepatology. 2000 Feb;31(2):474-9 [10655273.001]
  • [Cites] Am J Pathol. 1983 Sep;112(3):357-82 [6311021.001]
  • [Cites] Science. 1983 Aug 12;221(4611):667-9 [6867736.001]
  • [Cites] Dig Dis Sci. 1988 Dec;33(12):1632-6 [3264236.001]
  • (PMID = 16758166.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 57
  •  go-up   go-down


38. Prins GS, Birch L, Tang WY, Ho SM: Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reprod Toxicol; 2007 Apr-May;23(3):374-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • If estrogenic exposures are abnormally high during the critical developmental period, permanent alterations in prostate morphology and function are observed, a process referred to as developmental estrogenization.
  • Using the neonatal rodent as an animal model, it has been shown that early exposure to high doses of estradiol results in an increased incidence of prostatic lesions with aging which include hyperplasia, inflammatory cell infiltration and prostatic intraepithelial neoplasia or PIN, believed to be the precursor lesion for prostatic adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Reproductive Hazards.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 1995 Mar;136(3):1303-14 [7867585.001]
  • [Cites] Proc Soc Exp Biol Med. 1995 Jan;208(1):116-9 [7534422.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):778-88 [7717601.001]
  • [Cites] Carcinogenesis. 1995 Jun;16(6):1311-7 [7788848.001]
  • [Cites] Acta Anat (Basel). 1995;153(1):1-11 [8560954.001]
  • [Cites] BMJ. 1996 Aug 10;313(7053):337-41 [8760741.001]
  • [Cites] J Biol Chem. 1996 Dec 13;271(50):31779-82 [8943214.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2056-61 [9050904.001]
  • [Cites] Endocrinology. 1997 May;138(5):1801-9 [9112371.001]
  • [Cites] Br J Urol. 1997 Apr;79 Suppl 2:18-26 [9126066.001]
  • [Cites] Dev Dyn. 1997 May;209(1):127-38 [9142502.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4356-9 [9331098.001]
  • [Cites] Endocrinology. 1998 Mar;139(3):874-83 [9492016.001]
  • [Cites] Endocrinology. 1999 Jan;140(1):405-15 [9886852.001]
  • [Cites] Cell. 1999 Jan 22;96(2):225-33 [9988217.001]
  • [Cites] Endocrinology. 1999 Jun;140(6):2801-13 [10342871.001]
  • [Cites] Natl Cancer Inst Monogr. 1963 Oct;12:1-27 [14072991.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Nov;92(4):237-53 [15663987.001]
  • [Cites] Dev Biol. 2005 Feb 15;278(2):396-414 [15680359.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):7014-9 [15867144.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6089-97 [11507058.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3092-6 [11595700.001]
  • [Cites] Biol Reprod. 2001 Nov;65(5):1496-505 [11673267.001]
  • [Cites] Biol Reprod. 2001 Nov;65(5):1506-17 [11673268.001]
  • [Cites] Reprod Fertil Dev. 2001;13(4):241-52 [11800163.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1370-6 [11888907.001]
  • [Cites] Environ Health Perspect. 2002 Apr;110(4):427-31 [11940462.001]
  • [Cites] Prostate. 2002 Jun 1;52(1):69-81 [11992621.001]
  • [Cites] J Urol. 2002 Jul;168(1):9-12 [12050481.001]
  • [Cites] Endocrinology. 2002 Sep;143(9):3628-40 [12193579.001]
  • [Cites] Toxicol Appl Pharmacol. 2002 Aug 15;183(1):10-22 [12217638.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):268-76 [12432276.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5493-6 [12493749.001]
  • [Cites] Development. 2003 May;130(10):2061-9 [12668621.001]
  • [Cites] Anticancer Drugs. 2003 Jun;14(5):377-81 [12782945.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4841-50 [12960060.001]
  • [Cites] Clin Prostate Cancer. 2003 Jun;2(1):24-31 [15046680.001]
  • [Cites] J Androl. 2004 May-Jun;25(3):330-7 [15064308.001]
  • [Cites] Reprod Toxicol. 2004 May;18(3):399-406 [15082075.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 15;68(6):981-8 [15313391.001]
  • [Cites] Dev Biol. 2004 Sep 15;273(2):257-75 [15328011.001]
  • [Cites] J Clin Endocrinol Metab. 1974 Jan;38(1):113-25 [4809636.001]
  • [Cites] Endocr Rev. 2005 Oct;26(6):833-76 [15901667.001]
  • [Cites] J Urol. 2005 Nov;174(5):2051-3 [16217392.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5624-32 [16740699.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1089:1-13 [17261752.001]
  • [Cites] Regul Toxicol Pharmacol. 1999 Oct;30(2 Pt 1):156-66 [10536110.001]
  • [Cites] Prostate. 1999 Nov 1;41(3):203-7 [10517879.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):221-3 [10698486.001]
  • [Cites] Leuk Lymphoma. 2000 Mar;37(1-2):39-51 [10721768.001]
  • [Cites] Endocrinology. 2000 Sep;141(9):3471-7 [10965920.001]
  • [Cites] Mol Cell Endocrinol. 2000 Jun;164(1-2):109-16 [11026563.001]
  • [Cites] Endocrinology. 2001 Jan;142(1):359-69 [11145599.001]
  • [Cites] Endocr Rev. 2001 Jun;22(3):319-41 [11399747.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):1971-2 [11493633.001]
  • [Cites] Prostate. 1994;24(2):67-78 [7508622.001]
  • [Cites] J Androl. 1994 Mar-Apr;15(2):97-9 [8056642.001]
  • [Cites] Endocrinology. 1975 Oct;97(4):898-907 [1193012.001]
  • [Cites] Invest Urol. 1978 Nov;16(3):186-90 [711410.001]
  • [Cites] Endocrinology. 1979 May;104(5):1442-6 [86439.001]
  • [Cites] Gan. 1978 Dec;69(6):861-2 [750279.001]
  • [Cites] Invest Urol. 1979 Jul;17(1):3-8 [447483.001]
  • [Cites] Obstet Gynecol. 1980 Nov;56(5):537-42 [7432722.001]
  • [Cites] Int Rev Cytol. 1983;84:235-68 [6358105.001]
  • [Cites] Acta Endocrinol (Copenh). 1986 Jul;112(3):447-56 [3751459.001]
  • [Cites] J Urol. 1986 Nov;136(5):1136-40 [3773083.001]
  • [Cites] Teratog Carcinog Mutagen. 1987;7(4):411-22 [2442828.001]
  • [Cites] Endocr Rev. 1987 Aug;8(3):338-62 [3308446.001]
  • [Cites] Br J Cancer. 1988 Feb;57(2):216-8 [3358915.001]
  • [Cites] J Natl Cancer Inst. 1988 Sep 7;80(13):1045-53 [2457709.001]
  • [Cites] Prostate. 1989;15(2):195-210 [2678040.001]
  • [Cites] Prostate. 1990;17(1):19-30 [1696712.001]
  • [Cites] Biol Reprod. 1991 Aug;45(2):308-21 [1786296.001]
  • [Cites] Endocrinology. 1992 Jun;130(6):3703-14 [1597166.001]
  • [Cites] J Urol. 1993 Jun;149(6):1593-601 [8501817.001]
  • [Cites] Endocrinology. 1993 Jun;132(6):2342-50 [7684975.001]
  • [Cites] Endocrinology. 1993 Jun;132(6):2387-98 [8504743.001]
  • [Cites] Environ Health Perspect. 2005 Aug;113(8):926-33 [16079060.001]
  • [Cites] Endocrinology. 2005 Sep;146(9):4138-47 [15919749.001]
  • (PMID = 17123779.001).
  • [ISSN] 0890-6238
  • [Journal-full-title] Reproductive toxicology (Elmsford, N.Y.)
  • [ISO-abbreviation] Reprod. Toxicol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK040890; United States / NIEHS NIH HHS / ES / R21 ES012281; United States / NIEHS NIH HHS / ES / R01 ES015584; United States / NIEHS NIH HHS / ES / ES12281; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NIDDK NIH HHS / DK / DK40890
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens
  • [Number-of-references] 90
  • [Other-IDs] NLM/ NIHMS23013; NLM/ PMC1927084
  •  go-up   go-down


39. Adams H, Liebisch P, Schmid P, Dirnhofer S, Tzankov A: Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms. Appl Immunohistochem Mol Morphol; 2009 Mar;17(2):96-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms.
  • The specificity and sensitivity of CD19, CD20, CD79a, and PAX5 for detection of B-cell lineage lymphoma/leukemia derivation was determined on tissue microarrays containing 148 Hodgkin lymphomas, 358 B-cell and 16 T-cell lymphomas, 50 myelomas, and 69 acute leukemias.
  • CD19 had the weakest specificity, because it was expressed in 3 T-cell lymphomas, but its sensitivity was better than CD79a.
  • In Hodgkin lymphoma cases, the presence of B-cell markers in Hodgkin and Reed-Sternberg cells decreased in the following order: PAX5>CD20>CD79a>CD19.
  • In conclusion, an optimal B-cell lineage panel for daily routine on paraffin-embedded tissues should consist of CD20 and CD79a, and eventually, PAX5 for mature lymphoid neoplasms and PAX5 and CD19, and eventually, CD20 in (acute) precursor cell leukemias, because they cover most of the sensitivity and specificity needed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838917.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD20; 0 / Antigens, CD79; 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / PAX5 protein, human
  •  go-up   go-down


40. Secchiero P, Zorzet S, Tripodo C, Corallini F, Melloni E, Caruso L, Bosco R, Ingrao S, Zavan B, Zauli G: Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS One; 2010;5(6):e11140
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts.
  • BACKGROUND: Although multimodality treatment can induce high rate of remission in many subtypes of non-Hodgkin's lymphoma (NHL), significant proportions of patients relapse with incurable disease.
  • The effect of human bone marrow (BM) mesenchymal stem cells (MSC) on tumor cell growth is controversial, and no specific information is available on the effect of BM-MSC on NHL.
  • Intra-peritoneal (i.p.) injection of MSC (4 days after i.p. injection of lymphoma cells) significantly increased the overall survival at an optimal MSC:lymphoma ratio of 1:10 in both xenograft models (BJAB+MSC, median survival = 58.5 days; SKW6.4+MSC, median survival = 40 days).
  • In in vitro experiments, we found that: i) MSC/lymphoma co-cultures modestly affected lymphoma cell survival and were characterized by increased release of pro-angiogenic cytokines with respect to the MSC, or lymphoma, cultures;.
  • ii) MSC induce the migration of endothelial cells in transwell assays, but promoted endothelial cell apoptosis in direct MSC/endothelial cell co-cultures.
  • CONCLUSIONS/SIGNIFICANCE: Our data demonstrate that BM-MSC exhibit anti-lymphoma activity in two distinct xenograft SCID mouse models of disseminated NHL.
  • [MeSH-major] Hematopoietic Stem Cells / cytology. Lymphoma, Non-Hodgkin / pathology. Mesenchymal Stromal Cells / cytology

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2007 Jul;31(7):899-906 [17241660.001]
  • [Cites] Curr Drug Metab. 2007 May;8(4):395-403 [17504227.001]
  • [Cites] Nat Med. 2007 Aug;13(8):944-51 [17632527.001]
  • [Cites] PLoS One. 2009;4(4):e4992 [19352430.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4197-205 [19036701.001]
  • [Cites] Leukemia. 2009 May;23(5):925-33 [19148141.001]
  • [Cites] Cancer Cell. 2009 Jun 2;15(6):527-38 [19477431.001]
  • [Cites] Cytotherapy. 2009;11(4):375-6 [19568969.001]
  • [Cites] Virology. 2010 Feb 20;397(2):369-78 [20004457.001]
  • [Cites] Int J Cancer. 2010 May 15;126(10):2308-18 [19816927.001]
  • [Cites] Biochemistry. 2010 Apr 20;49(15):3282-8 [20235595.001]
  • [Cites] Cell Mol Life Sci. 2004 Aug;61(15):1965-74 [15289937.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Leukemia. 2008 Mar;22(3):593-9 [18185520.001]
  • [Cites] PLoS One. 2008;3(4):e1886 [18382669.001]
  • [Cites] Blood. 2008 May 1;111(9):4551-8 [18256324.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4331-9 [18519693.001]
  • [Cites] Leuk Res. 2008 Oct;32(10):1565-72 [18407351.001]
  • [Cites] Stem Cells. 2008 Jun;26(6):1387-94 [18388305.001]
  • [Cites] Int J Cancer. 2008 Nov 15;123(10):2229-38 [18777559.001]
  • [Cites] Cytotherapy. 2008;10(7):657-67 [18985472.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2015-23 [11932904.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3837-44 [12881305.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):47-56 [14751137.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7837-41 [6818551.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 3;96(21):1593-603 [15523088.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1815-22 [15494428.001]
  • [Cites] Cancer Sci. 2005 Mar;96(3):149-56 [15771617.001]
  • [Cites] Blood. 2005 May 1;105(9):3413-9 [15644410.001]
  • [Cites] J Exp Med. 2006 May 15;203(5):1235-47 [16636132.001]
  • [Cites] Exp Mol Pathol. 2006 Jun;80(3):267-74 [16214129.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5622-31 [17020964.001]
  • [Cites] Blood. 2007 Jan 15;109(2):693-702 [16985173.001]
  • [Cites] Leukemia. 2007 Feb;21(2):304-10 [17170725.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):1049-57 [17380207.001]
  • [Cites] Haematologica. 2007 Apr;92(4):440-9 [17488654.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1521-31 [17476277.001]
  • (PMID = 20585401.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2886845
  •  go-up   go-down


41. Gan RL, Lan K, Yin ZH, Wang LJ, Song Y, Yao KT: Construction of hu-PBL/SCID chimeras and development of EBV-related lymphomas. Chin Med Sci J; 2005 Mar;20(1):16-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To construct hu-PBL/SCID chimeras and to investigate the development of lymphoma and oncogenicity of the Epstein-Barr virus (EBV).
  • Mice with hu-PBL engraftment from healthy EBV seronegative donors were injected intraperitoneally with EBV-containing supernatant from suspension culture of B95-8 cell line (active infection), whereas mice receiving lymphocytes from healthy EBV seropositive donors were not re-infected with B95-8 derived EBV (latent infection).
  • Histological morphology of tumors exhibited diffuse large cell lymphomas.
  • CONCLUSIONS: EBV-induced tumors were human B-cell malignant lymphomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15844306.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Lysosomal-Associated Membrane Protein 1; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


42. Bagheri K, Alimoghadam K, Pourfathollah AA, Hassan ZM, Hajati J, Moazzeni SM: The efficient generation of immunocompetent dendritic cells from leukemic blasts in acute myeloid leukemia: a local experience. Pathol Oncol Res; 2009 Jun;15(2):257-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The morphology, expression of key surface molecules and allostimulatory activity of resultant DCs were compared with primary blasts and cultured but cytokine untreated control groups.
  • The potency of generated DCs to induce allogeneic T cell proliferation increased significantly compared to pre and post culture control groups (27,533.4 +/- 2,548.3, 8,820.4 +/- 1,639.4 and 3,200.35 +/- 976 respectively).
  • [MeSH-minor] Adult. Antigen-Presenting Cells. Cell Differentiation. Cell Proliferation. Child. Child, Preschool. Female. Flow Cytometry. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Humans. Immunophenotyping. Interleukin-4 / pharmacology. Lymphocyte Activation. Male. Middle Aged. Peptidyl-Dipeptidase A / metabolism. Recombinant Proteins / pharmacology. Tumor Cells, Cultured. Tumor Necrosis Factor-alpha / pharmacology. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2008 May;14(5):556-67 [18410898.001]
  • [Cites] Immunopharmacol Immunotoxicol. 2008;30(1):91-104 [18306107.001]
  • [Cites] J Immunol. 2000 Dec 1;165(11):6278-86 [11086063.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2184-90 [12424204.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 May;14(5):518-30 [18410894.001]
  • [Cites] Haematologica. 2008 Apr;93(4):633-4 [18379012.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2381-6 [18067014.001]
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Feb;14(1):137-41 [16584610.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):99-109 [18158966.001]
  • [Cites] Blood. 1990 Jun 15;75(12):2292-8 [1693526.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1653-61 [17145602.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2003 Jul;24(7):365-8 [12941192.001]
  • [Cites] Bone Marrow Transplant. 1990 Sep;6(3):155-61 [2252954.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]
  • [Cites] Curr Opin Hematol. 2008 Mar;15(2):108-14 [18300756.001]
  • [Cites] J Immunol. 2001 Nov 15;167(10):6021-30 [11698483.001]
  • [Cites] Blood. 2001 May 1;97(9):2764-71 [11313269.001]
  • [Cites] Leuk Res. 2003 Sep;27(9):795-802 [12804637.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1755-66 [10815894.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):782-91 [18410450.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2048-55 [10477734.001]
  • [Cites] Exp Hematol. 2001 Jun;29(6):709-19 [11378266.001]
  • [Cites] Eur J Immunol. 2008 Mar;38(3):750-62 [18236400.001]
  • [Cites] Ann Hematol. 2000 Jul;79(7):355-62 [10965783.001]
  • [Cites] Br J Haematol. 1998 Dec;103(3):763-71 [9858228.001]
  • [Cites] Blood. 1986 Dec;68(6):1355-62 [3465377.001]
  • [Cites] Leukemia. 1999 Aug;13(8):1175-87 [10450745.001]
  • [Cites] J Immunol. 2001 Sep 1;167(5):2479-86 [11509586.001]
  • [Cites] Zhejiang Da Xue Xue Bao Yi Xue Ban. 2005 Jul;34(4):348-52, 357 [16059984.001]
  • [Cites] Blood. 1999 Feb 1;93(3):780-6 [9920826.001]
  • [Cites] J Clin Immunol. 2005 Mar;25(2):87-98 [15821885.001]
  • [Cites] Leukemia. 2002 Jan;16(1):84-93 [11840267.001]
  • [Cites] Br J Haematol. 2003 Jan;120(1):63-73 [12492578.001]
  • [Cites] Exp Hematol. 2008 Apr;36(4):433-42 [18249061.001]
  • [Cites] Hum Immunol. 2000 Jun;61(6):565-74 [10825585.001]
  • [Cites] J Clin Immunol. 2008 Jul;28(4):390-7 [18347959.001]
  • [Cites] Acta Haematol. 1996;95(3-4):257-62 [8677752.001]
  • [Cites] Ann Hematol. 1999 Apr;78(4):181-6 [10348149.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4497-506 [12907623.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1168-76 [8683998.001]
  • [Cites] Prog Clin Biol Res. 1987;244:401-8 [3310002.001]
  • [Cites] Int J Cancer. 2000 May 1;86(3):385-92 [10760827.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):473-81 [18176612.001]
  • [Cites] Exp Hematol. 2003 Dec;31(12):1301-9 [14662338.001]
  • [Cites] Clin Exp Immunol. 2001 Dec;126(3):403-11 [11737054.001]
  • [Cites] Leukemia. 2001 Apr;15(4):668-9 [11368375.001]
  • [Cites] Haematologica. 2008 Apr;93(4):594-600 [18322250.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4319-30 [17848619.001]
  • [Cites] Stem Cells. 2000;18(2):139-47 [10742386.001]
  • [Cites] Haematologica. 2006 Mar;91(3):348-55 [16531258.001]
  • [Cites] Am J Hematol. 2008 Jun;83(6):446-50 [18247382.001]
  • [Cites] Korean J Lab Med. 2007 Oct;27(5):305-12 [18094593.001]
  • [Cites] Blood. 1983 Mar;61(3):443-8 [6572076.001]
  • [Cites] Eur J Immunol. 1998 Jan;28(1):90-103 [9485189.001]
  • (PMID = 18807213.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 3.4.15.1 / Peptidyl-Dipeptidase A
  •  go-up   go-down


43. Cooper AC, Karp RM, Clark EJ, Taghizadeh NR, Hoyt JG, Labenski MT, Murray MJ, Hannig G, Westlin WF, Thompson CD: A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo. Clin Cancer Res; 2006 Apr 15;12(8):2583-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo.
  • EXPERIMENTAL DESIGN: To examine the activity of PPI-2458 on germinal center morphology, spleen sections from cynomolgus monkeys treated with oral PPI-2458 were analyzed.
  • [MeSH-major] Aminopeptidases / antagonists & inhibitors. Cell Proliferation / drug effects. Epoxy Compounds / pharmacology. Lymphoma, Non-Hodgkin / drug therapy. Metalloendopeptidases / antagonists & inhibitors. Valine / analogs & derivatives
  • [MeSH-minor] Animals. B-Lymphocytes / drug effects. B-Lymphocytes / pathology. Blotting, Western. Cell Line, Tumor. Dose-Response Relationship, Drug. Female. Germinal Center / drug effects. Germinal Center / pathology. Humans. Lymphocyte Count. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Macaca fascicularis. Mice. Mice, SCID. Proto-Oncogene Proteins c-bcl-2 / metabolism. Time Factors. Xenograft Model Antitumor Assays / methods

  • Hazardous Substances Data Bank. L-Valine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638869.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epoxy Compounds; 0 / PPI 2458; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.4.11.- / Aminopeptidases; EC 3.4.11.18 / methionine aminopeptidase 2; EC 3.4.24.- / Metalloendopeptidases; HG18B9YRS7 / Valine
  •  go-up   go-down


44. Prata Kde L, Orellana MD, De Santis GC, Kashima S, Fontes AM, Carrara Rde C, Palma PV, Neder L, Covas DT: Effects of high-dose chemotherapy on bone marrow multipotent mesenchymal stromal cells isolated from lymphoma patients. Exp Hematol; 2010 Apr;38(4):292-300.e4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of high-dose chemotherapy on bone marrow multipotent mesenchymal stromal cells isolated from lymphoma patients.
  • OBJECTIVE: High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation is a widely applied treatment for hematological and autoimmune diseases.
  • MATERIALS AND METHODS: We studied 12 consecutive lymphoma patients submitted to BEAM conditioning regimen followed by autologous stem cell transplantation 28 to 1836 days before the sample collection.
  • RESULTS: The cell population isolated showed a typical MSC morphology, immunophenotype, and differentiation capacity into adipogenic, osteogenic, and chondrogenic lineages.
  • The MSCs obtained from patients with Hodgkin's disease and non-Hodgkin's lymphoma showed decreased fibroblastoid colony-forming unit count (p = 0.023) and increased doubling time (p = 0.031) related to the control group.
  • The total cell expansion of MSCs from normal subjects was marginally superior to the patient group (p = 0.064).
  • CONCLUSIONS: Results suggest that HDCT applied to lymphoma patients damaged MSCs, which was demonstrated by their reduced clonogenic potential, doubling time, and cell expansion rates when compared to controls.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols. Bone Marrow Cells / drug effects. Hodgkin Disease. Lymphoma, Non-Hodgkin. Mesenchymal Stromal Cells / drug effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20138957.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


45. Dai HP, Xue YQ, Zhang J, Wu YF, Pan JL, Wang Y, Shen J: Translocation t(2;8)(p12;q24) in two patients with B Cell chronic lymphocytic leukemia. Acta Haematol; 2008;120(4):232-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation t(2;8)(p12;q24) in two patients with B Cell chronic lymphocytic leukemia.
  • It is well known that translocation between chromosomes 2 and 8, t(2;8)(p12;q24), has a strong association with Burkitt's lymphoma.
  • They were diagnosed as having typical CLL (case 1) and CLL/prolymphocytic leukemia (case 2), respectively, based on morphology and immunophenotyping.
  • Karyotypic analysis of the bone marrow cells using the R-banding technique revealed a karyotype of 47,XY, t(2;8)(p12;q24), +4,[17]/46, XY[9] in case 1 and a karyotype of 45,X, t(Y;7)(q12;q21),t(2;8)(p12; q24),del(12)(p12),-17[5]/46,XY[9] in case 2.
  • [MeSH-major] Chromosomes, Human, Pair 2. Chromosomes, Human, Pair 8. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19246886.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


46. Malikhova OA, Poddubnyĭ BK, Poddubnaia IV, Moskalenko OA, Kontsevaia AIu: [Endoscopic criteria for diagnosis of various macroscopic variants of non-Hodgkin's gastric lymphoma]. Eksp Klin Gastroenterol; 2010;(9):33-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic criteria for diagnosis of various macroscopic variants of non-Hodgkin's gastric lymphoma].
  • PURPOSE: The purpose of our investigation was working out of non-Hodgkin's gastric lymphoma endoscopic criteria.
  • MATERIALS AND METHODS: We examinated 250 patients with gastric lymphoma, from those primary and secondary lesions were in 160 (64%) cases and 90 (36%) cases, respectively.
  • Diagnosis of lymphoma was confirmed by morphology and immunohistochemistry.
  • Separately should was noted, that almost in one third cases primary gastric lymphoma was diagnosed after one year.
  • The second endpoint of our work was detection of macroscopic features depending on morphological variant of lymphoma.
  • Analysis of represented data demonstrated prevalence similar to gastritis form (33.4%) for MALT-lymphoma, infiltrative-ulcerous form as for diffuse large-cell B-cell lymphoma of MALT-type, as for diffuse large-cell B-cell lymphoma--45.0% and 41.1%, respectively.
  • Infiltrative form was more often in group of patients with follicular lymphoma--31.8%, and ulcerous form predominated for Burkett's lymphoma--60.0%.
  • CONCLUSION; Were established the most informative endoscopic criteria for diagnosis non-Hodgkin's gastric lymphoma.
  • [MeSH-major] Gastroscopy. Lymphoma, Non-Hodgkin / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21427921.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


47. Ly-Sunnaram B, Henry C, Gandemer V, Mee FL, Burtin F, Blayau M, Cayuela JM, Oster M, Clech P, Rambeau M, Marie C, Pampin C, Edan C, Gall EL, Goasguen JE: Late ovarian relapse of TEL/AML1 positive ALL confirming that TEL deletion is a secondary event in leukemogenesis. Leuk Res; 2005 Sep;29(9):1089-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe here a late extramedullary ovarian relapse in an 18-year-old female who was diagnosed with hypotetraploid cell acute lymphoblastic leukaemia (cALL) at the age of 6.
  • At both occurrences of the disease cells were analyzed by morphology, immunophenotyping, cytogenetics and molecular methods.
  • [MeSH-major] Gene Deletion. Oncogene Proteins, Fusion / genetics. Ovarian Neoplasms / secondary. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038737.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


48. Dong HY, Scadden DT, de Leval L, Tang Z, Isaacson PG, Harris NL: Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol; 2005 Dec;29(12):1633-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm.
  • AIDS-associated aggressive B-cell lymphomas often have plasmacytoid features.
  • Plasma cell neoplasms in HIV patients were commonly described to have atypical morphology and an aggressive clinical course in the literature.
  • Of these, 13 of 14 had homogeneous morphology and were generally CD45(+), CD20-, PAX-5-, and CD138(+).
  • The 14th patient who had a nodal disease with more undifferentiated morphology and expression of the HHV8 LNA protein was alive without disease at last follow-up (>72 months), probably representing a novel HHV8(+) lymphoma.
  • We conclude that most plasmacytic tumors in HIV-positive individuals are extramedullary, clinically aggressive EBV(+) tumors identical to plasmablastic lymphoma that does not have the clinical features of plasma cell myeloma.
  • [MeSH-major] HIV Seropositivity. Herpesvirus 4, Human / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, AIDS-Related / virology. Multiple Myeloma / pathology


49. Bhagavathi S, Wilson JD: Primary central nervous system lymphoma. Arch Pathol Lab Med; 2008 Nov;132(11):1830-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is an uncommon extranodal non-Hodgkin lymphoma.
  • Diffuse large B-cell lymphomas constitute most PCNSLs, whereas T-cell, low-grade, anaplastic, and Hodgkin lymphomas are rarely encountered.
  • The morphology of PCNSL shows a characteristic angiocentric pattern and is positive for B-cell markers by immunohistochemistry.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976024.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


50. Neves Mascarenhas A, Papadia C, Alves Aquino C, Oba L, Ferreira M, Casulari LA: Treatment for acute lymphoblastic leukemia in children is associated with papillary carcinoma of thyroid, but not with thyroid disfunction. Minerva Pediatr; 2006 Oct;58(5):469-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the thyroid gland morphology and the function of the pituitary-thyroid axis in a group of patients treated for ALL in childhood.
  • Thyroid morphology (n=33) was evaluated by palpation and ultrasonography.
  • [MeSH-major] Carcinoma, Papillary / blood. Carcinoma, Papillary / etiology. Neoplasms, Second Primary / blood. Neoplasms, Second Primary / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Thyroid Gland / drug effects. Thyroid Neoplasms / blood. Thyroid Neoplasms / etiology. Thyroxine / blood. Triiodothyronine / blood

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008858.001).
  • [ISSN] 0026-4946
  • [Journal-full-title] Minerva pediatrica
  • [ISO-abbreviation] Minerva Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 06LU7C9H1V / Triiodothyronine; 5Y5F15120W / Thyrotropin-Releasing Hormone; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


51. Sagaert X, Theys T, De Wolf-Peeters C, Marynen P, Baens M: Splenic marginal zone lymphoma-like features in API2-MALT1 transgenic mice that are exposed to antigenic stimulation. Haematologica; 2006 Dec;91(12):1693-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic marginal zone lymphoma-like features in API2-MALT1 transgenic mice that are exposed to antigenic stimulation.
  • Our results showed that the expression of API2-MALT1 is not sufficient to induce the development of lymphoma masses.
  • Here, we demonstrate that immunization with Freund's complete adjuvant led to the loss of compartmentalization of the splenic white pulp in API2-MALT1 transgenic mice, resulting in a splenic marginal zone lymphoma-like lymphoid hyperplasia of a peculiar B-cell subset that disappeared as soon as the antigenic stimulation faded away.
  • [MeSH-major] Freund's Adjuvant / immunology. Lymphoma / genetics. Lymphoma / pathology. Oncogene Proteins, Fusion / genetics. Splenic Neoplasms / genetics. Splenic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145608.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Oncogene Proteins, Fusion; 9007-81-2 / Freund's Adjuvant
  •  go-up   go-down


52. Wang W, Gao L, Wang LL, Li MY, Li YY, Zhao W, Xu YY, Ding Y, Yu L: [Detection of bone marrow involvement by lymphoma cells in patients with B-NHL by using flow cytometry analysis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1204-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of bone marrow involvement by lymphoma cells in patients with B-NHL by using flow cytometry analysis].
  • This study was purposed to investigate the significance of using (FCM) flow cytometry for detection bone marrow involvement by lymphoma cells in untreated patients with B cell non-Hodgkin's lymphoma (B-NHL).
  • Bone marrow involvement was diagnosed based on the results of morphology, FCM and molecular biology.
  • The results indicated that the positive ratios of bone marrow involvement were different detected by three methods, the most sensitive method was FCM (positive rate was 27.5%), the moderately sensitive method was molecular biology (positive rate was 22.2%), the inferior method was morphology method (positive rate was 5.6%).
  • Even in patients with early stage, lymphoma cells still could be detected by FCM in involved bone marrow.
  • Evaluation whether the bone marrow has been involved by lymphoma cells should be recommend to every patient with B-NHL before chemotherapy and every disease stages.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129261.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


53. Gualco G, Chioato L, Harrington WJ Jr, Weiss LM, Bacchi CE: Primary and secondary T-cell lymphomas of the breast: clinico-pathologic features of 11 cases. Appl Immunohistochem Mol Morphol; 2009 Jul;17(4):301-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary and secondary T-cell lymphomas of the breast: clinico-pathologic features of 11 cases.
  • Breast involvement by non-Hodgkin lymphomas is rare, and exceptional for T-cell lymphomas; we studied the morphologic, immunophenotypic, and clinical features of 11 patients with T-cell non-Hodgkin lymphomas involving the breast.
  • One primary breast lymphomas was T-cell lymphoma unspecified, other was subcutaneous panniculitis-like T-cell lymphoma, and 2 cases were anaplastic large cell lymphomas.
  • One of the anaplastic large cell lymphoma cases was found surrounding a silicone breast implant and presented as clinically as mastitis; whereas the other case occurred in a man.
  • T-cell lymphoma secondarily involved the breast in 7 patients, all women and 1 bilateral, with a median age of 29 years.
  • Three patients had adult T-cell leukemia/lymphoma, including the patient with bilateral lesions, 3 others had precursor T-lymphoblastic lymphoma/leukemia, and the other presented with a peripheral-T-cell lymphoma non otherwise specified type.
  • Breast T-cell lymphomas are very infrequent and are morphologically and clinically heterogeneous.

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2008 Oct;16(4):407-13 [18480397.001]
  • [Cites] Mod Pathol. 2000 Jun;13(6):599-605 [10874662.001]
  • [Cites] Breast J. 2002 Sep-Oct;8(5):294-304 [12199758.001]
  • [Cites] Rev Soc Bras Med Trop. 2002 Sep-Oct;35(5):499-508 [12621671.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e115-8 [12653596.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Haematologica. 2004 Apr;89(4):ELT01 [15075114.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):833-6 [15160967.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Cancer. 1972 Jun;29(6):1705-12 [4555557.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2602-11 [2249200.001]
  • [Cites] Cancer. 1991 Mar 1;67(5):1359-69 [1991299.001]
  • [Cites] Diagn Mol Pathol. 1993 Jun;2(2):99-107 [8269284.001]
  • [Cites] Am J Surg Pathol. 1994 Mar;18(3):288-95 [8116797.001]
  • [Cites] JAMA. 1995 Jan 11;273(2):116 [7799490.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):712-7 [7755157.001]
  • [Cites] J Am Acad Dermatol. 1995 Dec;33(6):1060-1 [7490360.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3124-8 [8874212.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] APMIS. 1997 Jun;105(6):445-8 [9236861.001]
  • [Cites] Plast Reconstr Surg. 1997 Aug;100(2):554-5 [9252643.001]
  • [Cites] Hematol Oncol. 1997 Feb;15(1):33-8 [9378471.001]
  • [Cites] Breast Cancer. 2005;12(2):154-8 [15858449.001]
  • [Cites] J Ultrasound Med. 2005 Oct;24(10):1453-60 [16179634.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):561-4 [16983530.001]
  • [Cites] Indian J Pathol Microbiol. 2007 Oct;50(4):816-8 [18306567.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):455-63 [18223553.001]
  • [Cites] Int J Hematol. 2008 Jun;87(5):491-7 [18414980.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2008 Jul;61(7):822-5 [17509956.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1299-309 [18636016.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):115-9 [11908714.001]
  • [Cites] Cancer. 2002 Apr 25;96(2):110-6 [11954028.001]
  • (PMID = 19318917.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / CA121935-03; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA121935-03; United States / NCI NIH HHS / CA / R01 CA121935
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS125674; NLM/ PMC2739299
  •  go-up   go-down


54. Zhang L, Talwalkar SS, Shaheen SP 2nd: A case of primary unilateral adrenal Burkitt-like large cell lymphoma presenting as adrenal insufficiency. Ann Diagn Pathol; 2007 Apr;11(2):127-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary unilateral adrenal Burkitt-like large cell lymphoma presenting as adrenal insufficiency.
  • Primary adrenal lymphoma is extraordinarily rare, in comparison with secondary adrenal involvement by non-Hodgkin lymphoma.
  • Primary adrenal lymphoma most commonly manifests with diffuse large B-cell morphology.
  • Burkitt-like large cell lymphoma morphology has been previously reported only once, to our knowledge.
  • We report an 80-year-old man presenting with unilateral primary adrenal lymphoma showing Burkitt-like morphology and adrenal insufficiency.
  • Fine needle aspiration yielded a dispersed population of monomorphic, medium to large cells suggestive of lymphoma.
  • Although dispersed cell populations cytologically favor lymphoma, metastatic poorly differentiated carcinoma and adrenal cortical carcinoma can manifest similarly.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Insufficiency / pathology. Burkitt Lymphoma / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349573.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


55. Raimondi SC, Zhou Y, Shurtleff SA, Rubnitz JE, Pui CH, Behm FG: Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6-RUNX1 fusion, T-lineage immunophenotype, and favorable outcome. Cancer Genet Cytogenet; 2006 Aug;169(1):50-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with near-triploidy or near-tetraploidy were more likely than those with high-hyperdiploidy (51-67 chromosomes) (n = 159) to be female (P = 0.05) and have T-lineage ALL (P = 0.02), L2 morphology (P < 0.0001), or the ETV6-RUNX1 fusion (P < 0.0001).
  • [MeSH-major] B-Lymphocytes / immunology. Core Binding Factor Alpha 2 Subunit / genetics. Oncogene Proteins, Fusion / genetics. Polyploidy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. T-Lymphocytes / immunology
  • [MeSH-minor] Cell Lineage. Child. Chromosome Banding. Flow Cytometry. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence


56. Guggisberg K, Jordan RC: Mantle cell lymphoma of the oral cavity: case series and comprehensive review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jan;109(1):98-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma of the oral cavity: case series and comprehensive review of the literature.
  • OBJECTIVE: Mantle cell lymphoma (MCL) is a rare B-cell neoplasm that has only recently been defined as a distinct entity.
  • Because of its rarity and histologic similarities to other small cell lymphomas, the microscopic diagnosis of MCL may be challenging.
  • Historical cases were reviewed, and available data regarding morphology, special stains, demographics, clinical presentation, radiographic findings, management, and outcome were extracted.
  • The microscopic diagnosis can be challenging, given its similar appearance to other small cell lymphomas, requiring a comprehensive immunohistochemical panel for the accurate diagnosis.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • [Cites] Clin Oncol (R Coll Radiol). 2004 May;16(3):186-92 [15191005.001]
  • [Cites] J Oral Pathol. 1987 Jan;16(1):8-12 [3104566.001]
  • [Cites] Blood. 1990 Oct 1;76(7):1387-91 [2207314.001]
  • [Cites] Blood. 1991 Jul 15;78(2):259-63 [2070063.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):802-111 [8478674.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):249-56 [7612490.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):257-62 [7612491.001]
  • [Cites] Am J Surg Pathol. 1996 May;20(5):627-40 [8619427.001]
  • [Cites] Curr Top Pathol. 1996;90:125-46 [8791750.001]
  • [Cites] Ear Nose Throat J. 1997 Jan;76(1):35-6 [9018933.001]
  • [Cites] J Oral Pathol Med. 1997 Jul;26(6):283-9 [9234189.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):567-75 [9452276.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):153-7 [11957138.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1785-91 [11681422.001]
  • [Cites] Ann Hematol. 2004 Feb;83(2):71-7 [14669040.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Sep;96(3):316-20 [12973287.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Nov;92(5):519-25 [11709688.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jun;34(4):391-5 [16053848.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):303-10 [15716836.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):77-81 [15621784.001]
  • [Cites] J Laryngol Otol. 1998 Oct;112(10):991-4 [10211231.001]
  • [Cites] Head Neck. 1999 May;21(3):247-54 [10208668.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):29-38 [16173960.001]
  • [Cites] Am J Surg Pathol. 1992 Jul;16(7):637-40 [1530105.001]
  • [Cites] Cancer. 2008 Aug 15;113(4):791-8 [18615506.001]
  • [Cites] Blood. 2008 Jan 15;111(2):558-65 [17962512.001]
  • [Cites] Histopathology. 2006 Mar;48(4):353-62 [16487357.001]
  • [Cites] Tumori. 2005 Nov-Dec;91(6):456-62 [16457141.001]
  • (PMID = 19880332.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / T32 DE017249; United States / NIDCR NIH HHS / DE / T32 DE017249-04; United States / NIDCR NIH HHS / DE / T32 DE017249-05; United States / NIDCR NIH HHS / DE / DE017249-04; United States / NIDCR NIH HHS / DE / T32 DE019096-02; United States / NIDCR NIH HHS / DE / DE017249-01; United States / NCI NIH HHS / CA / R21 CA095231; United States / NIDCR NIH HHS / DE / DE019096-02; United States / NIDCR NIH HHS / DE / T32 DE017249-03; United States / NCI NIH HHS / CA / R33 CA095231; United States / NIDCR NIH HHS / DE / T32 DE019096; United States / NIDCR NIH HHS / DE / T32DE017249; United States / NIDCR NIH HHS / DE / DE019096-01; United States / NIDCR NIH HHS / DE / T32 DE017249-02; United States / NIDCR NIH HHS / DE / DE017249-02; United States / NIDCR NIH HHS / DE / T32 DE019096-01; United States / NIDCR NIH HHS / DE / DE017249-03; United States / NIDCR NIH HHS / DE / T32 DE017249-01; United States / NIDCR NIH HHS / DE / DE017249-05; United States / NIDCR NIH HHS / DE / T32DE019096; United States / NCI NIH HHS / CA / CA095231
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 136601-57-5 / Cyclin D1
  • [Number-of-references] 29
  • [Other-IDs] NLM/ NIHMS156688; NLM/ PMC2818374
  •  go-up   go-down


57. Bartsch K, Al-Ali H, Reinhardt A, Franke C, Hudecek M, Kamprad M, Tschiedel S, Cross M, Niederwieser D, Gentilini C: Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used. Transplantation; 2009 Jan 27;87(2):217-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used.
  • To understand in more detail hematopoietic engraftment and immune modulation after hematopoietic cell transplantation, we investigated the ability of donor MSC to engraft after hematopoietic cell transplantation in dependency to the conditioning regimen (myeloablative vs. reduced intensity) and source of the graft (bone marrow vs. peripheral blood).
  • METHODS: Bone marrow MSC of 12 patients were analyzed, a median of 23.4 (range 0.9-137.8) months after human leukocyte antigen matched but gender mismatched bone marrow transplantation after myeloablative conditioning (n=4) or peripheral blood cell transplantation after myeloablative (n=4) or reduced intensity conditioning (n=4).
  • MSC were characterized by morphology, positivity for CD 105+, CD73+, CD 44+, and CD 90+, and by their capacity to differentiate into adipocytic and osteogenic cells.
  • [MeSH-major] Adult Stem Cells / drug effects. Bone Marrow Transplantation. Leukemia / surgery. Lymphoma, Non-Hodgkin / surgery. Mesenchymal Stem Cell Transplantation. Mesenchymal Stromal Cells / drug effects. Myeloablative Agonists / therapeutic use. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Cell Culture Techniques. Cell Proliferation / drug effects. Cell Separation. Female. Histocompatibility Testing. Humans. Immunophenotyping. Male. Middle Aged. Time Factors. Transplantation Chimera. Transplantation, Homologous. Young Adult


58. Zheng Y, Zhou M, Ye A, Li Q, Bai Y, Zhang Q: The conformation change of Bcl-2 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cells. World J Surg Oncol; 2010;8:31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As the role of Bcl-2 in arsenic trioxide-mediated cell apoptosis and conformation change of Bcl-2 in response to arsenic trioxide treatment has not been studied.
  • Proliferation was measured by using the Kit-8 cell counting assay.
  • Analysis of nuclear morphology was observed by DAPI staining.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Arsenicals / pharmacology. Cell Proliferation / drug effects. Oxides / pharmacology. Proto-Oncogene Proteins c-bcl-2 / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):662-7 [10639136.001]
  • [Cites] Int J Lab Hematol. 2010 Feb;32(1 Pt 1):e77-85 [19208092.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]
  • [Cites] World J Gastroenterol. 2002 Feb;8(1):36-9 [11833067.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3893-903 [12124315.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):55-64 [12838300.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8590-607 [14634621.001]
  • [Cites] Cell. 2004 Feb 20;116(4):527-40 [14980220.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):389-401 [15093545.001]
  • [Cites] Leuk Res. 2004 Sep;28(9):891-900 [15234563.001]
  • [Cites] J Cell Physiol. 1996 Nov;169(2):256-68 [8908193.001]
  • [Cites] Blood. 1999 Jan 1;93(1):268-77 [9864170.001]
  • [Cites] J Exp Ther Oncol. 2004 Dec;4(4):335-42 [15844663.001]
  • [Cites] World J Gastroenterol. 2005 Jun 14;11(22):3451-6 [15948253.001]
  • [Cites] Hematology. 2005 Jun;10(3):205-13 [16019469.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7255-63 [16243795.001]
  • [Cites] Oncogene. 2005 Oct 27;24(47):7031-42 [16007134.001]
  • [Cites] Oncol Res. 2005;15(5):249-55 [16261844.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):726-9 [16243384.001]
  • [Cites] Int J Cancer. 2006 Apr 1;118(7):1823-30 [16217749.001]
  • [Cites] Arch Toxicol. 2006 Jun;80(6):310-8 [16328441.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 29;348(3):1075-81 [16904648.001]
  • [Cites] Expert Opin Ther Targets. 2007 Jan;11(1):69-79 [17150035.001]
  • [Cites] Cancer Lett. 2007 Feb 8;246(1-2):122-8 [16569477.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):218-22 [17275888.001]
  • [Cites] Postepy Hig Med Dosw (Online). 2008;62:463-7 [18806735.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Dec;63(1):37-43 [18297286.001]
  • [Cites] Leuk Lymphoma. 2008 Oct;49(10):1976-81 [18949620.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 Nov;139(5):708-12 [18984268.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1126-32 [19228717.001]
  • [Cites] J Oral Pathol Med. 2009 Mar;38(3):307-13 [18710422.001]
  • [Cites] Cancer Res. 2009 Sep 1;69(17):6906-14 [19671798.001]
  • [Cites] Neurotoxicology. 2009 Sep;30(5):803-10 [19465052.001]
  • [Cites] Cancer Res. 2009 Dec 15;69(24):9346-53 [19934311.001]
  • [Cites] Oncology (Williston Park). 2000 Feb;14(2):206, 211, 215-6 passim [10736809.001]
  • (PMID = 20403207.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ PMC2873337
  •  go-up   go-down


59. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM: Reprogramming of miRNA networks in cancer and leukemia. Genome Res; 2010 May;20(5):589-99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / metabolism. Animals. Cell Line, Tumor. Gene Dosage. Humans. Lung / metabolism. Lung Neoplasms / metabolism. Mice. Oligonucleotide Array Sequence Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


60. Nicholson-Dykstra SM, Higgs HN: Arp2 depletion inhibits sheet-like protrusions but not linear protrusions of fibroblasts and lymphocytes. Cell Motil Cytoskeleton; 2008 Nov;65(11):904-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Arp2/3 complex-mediated assembly and protrusion of a branched actin network at the leading edge occurs during cell migration, although some studies suggest it is not essential.
  • In order to test the role of Arp2/3 complex in leading edge protrusion, Swiss 3T3 fibroblasts and Jurkat T cells were depleted of Arp2 and evaluated for defects in cell morphology and spreading efficiency.
  • Arp2-depleted fibroblasts exhibit severe defects in formation of sheet-like protrusions at early time points of cell spreading, with sheet-like protrusions limited to regions along the length of linear protrusions.
  • We conclude that Arp2/3 complex plays a significant role in assembly of sheet-like protrusions, especially during early stages of cell spreading, but is not required for assembly of a variety of linear actin-based protrusions.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] J Cell Biol. 1995 Oct;131(2):385-97 [7593166.001]
  • [Cites] J Cell Biol. 1995 Nov;131(4):989-1002 [7490299.001]
  • [Cites] Cell. 1996 Feb 9;84(3):371-9 [8608590.001]
  • [Cites] J Cell Biol. 1997 Jul 28;138(2):375-84 [9230079.001]
  • [Cites] Biochem J. 1997 Nov 15;328 ( Pt 1):105-12 [9359840.001]
  • [Cites] J Cell Biol. 1999 May 31;145(5):1009-26 [10352018.001]
  • [Cites] J Cell Biol. 1999 Sep 6;146(5):1097-106 [10477762.001]
  • [Cites] Mol Biol Cell. 2004 Dec;15(12):5197-207 [15385624.001]
  • [Cites] J Cell Sci. 2005 Jan 1;118(Pt 1):19-26 [15615780.001]
  • [Cites] Curr Opin Cell Biol. 2005 Feb;17(1):55-61 [15661519.001]
  • [Cites] Curr Biol. 2005 Jan 26;15(2):129-33 [15668168.001]
  • [Cites] J Cell Biol. 2005 Feb 14;168(4):619-31 [15716379.001]
  • [Cites] Mol Biol Cell. 2005 May;16(5):2443-57 [15758024.001]
  • [Cites] Curr Biol. 2005 May 10;15(9):R346-57 [15886095.001]
  • [Cites] Nat Cell Biol. 2005 Jun;7(6):619-25 [15908944.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16263-8 [16254049.001]
  • [Cites] Curr Opin Cell Biol. 2006 Feb;18(1):18-25 [16337369.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):4906-11 [16549794.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 16;103(20):7694-9 [16675552.001]
  • [Cites] Mol Biol Cell. 2006 Jun;17(6):2581-91 [16597702.001]
  • [Cites] Cell Motil Cytoskeleton. 2006 Jul;63(7):395-414 [16619224.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12411-6 [16894163.001]
  • [Cites] J Cell Biol. 2006 Sep 11;174(6):863-75 [16966425.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Oct;7(10):713-26 [16990851.001]
  • [Cites] Cell Mol Life Sci. 2006 Oct;63(19-20):2329-41 [16909209.001]
  • [Cites] Curr Biol. 2007 Jan 9;17(1):79-84 [17208190.001]
  • [Cites] J Cell Sci. 2007 Jan 15;120(Pt 2):340-52 [17200142.001]
  • [Cites] Cell. 2007 Feb 9;128(3):561-75 [17289574.001]
  • [Cites] Immunity. 2007 Feb;26(2):177-90 [17306570.001]
  • [Cites] Curr Biol. 2007 Mar 6;17(5):395-406 [17331727.001]
  • [Cites] J Cell Sci. 2007 Apr 1;120(Pt 7):1235-44 [17356063.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5425-30 [17369366.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2007;36:451-77 [17477841.001]
  • [Cites] J Cell Sci. 2007 Oct 1;120(Pt 19):3475-87 [17855386.001]
  • [Cites] Nat Cell Biol. 2007 Oct;9(10):1110-21 [17909522.001]
  • [Cites] J Cell Biol. 2007 Nov 19;179(4):777-91 [18025308.001]
  • [Cites] PLoS Biol. 2007 Nov;5(11):e317 [18044991.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20296-301 [18077330.001]
  • [Cites] Exp Cell Res. 2008 Feb 1;314(3):478-88 [18067889.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):306-13 [18278037.001]
  • [Cites] J Cell Biol. 2008 Mar 24;180(6):1245-60 [18362183.001]
  • [Cites] Mol Biol Cell. 2008 Apr;19(4):1561-74 [18256280.001]
  • [Cites] EMBO J. 2008 Apr 9;27(7):982-92 [18309290.001]
  • [Cites] Methods Cell Biol. 1998;56:253-75 [9500142.001]
  • [Cites] Biochemistry. 1999 Nov 16;38(46):15212-22 [10563804.001]
  • [Cites] Curr Biol. 2000 Nov 2;10(21):1387-90 [11084341.001]
  • [Cites] J Cell Sci. 2001 Dec;114(Pt 24):4557-65 [11792820.001]
  • [Cites] Biophys J. 2002 Sep;83(3):1237-58 [12202352.001]
  • [Cites] J Cell Sci. 2002 Dec 1;115(Pt 23):4649-60 [12415009.001]
  • [Cites] J Cell Biol. 2003 Feb 3;160(3):409-21 [12566431.001]
  • [Cites] J Cell Biol. 2003 Mar 17;160(6):951-62 [12642617.001]
  • [Cites] Curr Biol. 2003 Apr 1;13(7):534-45 [12676083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5819-22 [12721367.001]
  • [Cites] J Cell Biol. 2003 Sep 1;162(5):781-7 [12952932.001]
  • [Cites] J Cell Biol. 2003 Sep 15;162(6):1079-88 [12975351.001]
  • [Cites] Neuron. 2004 Jul 8;43(1):81-94 [15233919.001]
  • [Cites] Cell. 2004 Aug 6;118(3):363-73 [15294161.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1396-403 [15130947.001]
  • [Cites] Science. 2004 Sep 17;305(5691):1782-6 [15375270.001]
  • [Cites] Exp Cell Res. 1970 Mar;59(3):393-8 [4907703.001]
  • [Cites] Exp Cell Res. 1970 Jun;60(3):437-44 [5463639.001]
  • [Cites] Exp Cell Res. 1970 Oct;62(2):389-98 [5531377.001]
  • [Cites] Exp Cell Res. 1971 Aug;67(2):359-67 [5097522.001]
  • [Cites] J Cell Biol. 1975 Dec;67(3):725-43 [1202021.001]
  • [Cites] J Cell Biol. 1995 Jun;129(5):1275-86 [7775574.001]
  • (PMID = 18720401.001).
  • [ISSN] 1097-0169
  • [Journal-full-title] Cell motility and the cytoskeleton
  • [ISO-abbreviation] Cell Motil. Cytoskeleton
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM069818-05; United States / NIGMS NIH HHS / GM / R01 GM069818; United States / NIGMS NIH HHS / GM / R01 GM069818-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actin-Related Protein 2
  • [Other-IDs] NLM/ NIHMS88780; NLM/ PMC2757053
  •  go-up   go-down


61. Lefevre EA, Hein WR, Stamataki Z, Brackenbury LS, Supple EA, Hunt LG, Monaghan P, Borhis G, Richard Y, Charleston B: Fibrinogen is localized on dark zone follicular dendritic cells in vivo and enhances the proliferation and survival of a centroblastic cell line in vitro. J Leukoc Biol; 2007 Sep;82(3):666-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibrinogen is localized on dark zone follicular dendritic cells in vivo and enhances the proliferation and survival of a centroblastic cell line in vitro.
  • Follicular dendritic cells (FDC) in the germinal centers (GC) of secondary lymphoid organs increase the survival and proliferation of antigen-stimulated B cells and are pivotal for the affinity maturation of an antibody response and for maintenance of B cell immunological memory.
  • The dark zone (DZ) and the light zone (LZ) constitute distinct areas of the GC containing different subtypes of FDC as identified by their morphology and phenotype.
  • [MeSH-major] Cell Proliferation. Cell Survival / physiology. Dendritic Cells, Follicular / metabolism. Fibrinogen / physiology. Germinal Center / immunology
  • [MeSH-minor] Amino Acid Sequence. Animals. Antibodies, Monoclonal / immunology. Burkitt Lymphoma / immunology. Burkitt Lymphoma / pathology. Carcinoma, Hepatocellular / immunology. Carcinoma, Hepatocellular / pathology. Cattle. Cell Differentiation. Humans. Immunization. Liver Neoplasms / immunology. Liver Neoplasms / pathology. Lymphocyte Activation. Mice. Mice, Inbred BALB C. Molecular Sequence Data. Palatine Tonsil / metabolism. Receptors, Antigen, T-Cell, gamma-delta / immunology. Sequence Homology, Amino Acid. Sheep. Signal Transduction. T-Lymphocytes. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Leukoc Biol. 2007 Nov;82(5):1361
  • (PMID = 17550975.001).
  • [ISSN] 0741-5400
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BBS/E/I/00001432
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Receptors, Antigen, T-Cell, gamma-delta; 9001-32-5 / Fibrinogen
  •  go-up   go-down


62. Kojima M, Motoori T, Iijima M, Ono T, Yoshizumi T, Matsumoto M, Masawa N, Nakamura S: Florid monocytoid B-cell hyperplasia resembling nodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue type. A histological and immunohistochemical study of four cases. Pathol Res Pract; 2006;202(12):877-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Florid monocytoid B-cell hyperplasia resembling nodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue type. A histological and immunohistochemical study of four cases.
  • A pale ring of medium-to-large cells surrounding the follicles, namely a marginal zone distribution pattern, is the key criterion for diagnosing nodal marginal zone B-cell lymphoma (NMZBL).
  • The tumor cells of NMZBL occasionally exhibit the morphology of monocytoid B-cells (MBC).
  • [MeSH-major] B-Lymphocytes / pathology. Germinal Center / pathology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Pseudolymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989959.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


63. Park J, Lee MS, Yoo SM, Seo T: A novel protein encoded by Kaposi's sarcoma-associated herpesvirus open reading frame 36 inhibits cell spreading and focal adhesion kinase activation. Intervirology; 2007;50(6):426-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel protein encoded by Kaposi's sarcoma-associated herpesvirus open reading frame 36 inhibits cell spreading and focal adhesion kinase activation.
  • OBJECTIVE: Kaposi's sarcoma-associated herpesvirus (KSHV) is a gamma-herpesvirus implicated in the development of Kaposi's sarcoma, primary effusion lymphoma and some forms of multicentric Castleman's disease.
  • Cell morphology change by ORF36 protein was studied.
  • Moreover, the ORF36 protein altered cell morphology to a round shape, similar to the phenotype of FAK-deficient cells.
  • The kinase activity of ORF36 protein was required for the inhibition of cell spreading.
  • CONCLUSION: Our results collectively demonstrate that the KSHV ORF36 protein is a viral protein kinase that inhibits cell spreading and FAK activation.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18182822.001).
  • [ISSN] 1423-0100
  • [Journal-full-title] Intervirology
  • [ISO-abbreviation] Intervirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Viral Proteins; EC 2.7.- / Protein Kinases; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases
  •  go-up   go-down


64. Xu LP, Huang XJ, Liu DH, Chen YH, Shi HX, Chen DB: [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation]. Zhonghua Nei Ke Za Zhi; 2007 Dec;46(12):996-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation].
  • OBJECTIVE: To study the risk factors and clinical characteristics of post transplantation lymphoproliferative disorders (PTLD) after hematopoietic stem cell transplantation (HSCT).
  • The morphology of biopsy appeared as small B-lymphocytic lymphoma; there was no response to chemotherapy and the patients died.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Lymphoproliferative Disorders / diagnosis. Lymphoproliferative Disorders / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478915.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


65. Li L, Li GD, Jiang W, Yang WX, Liu WP, Li JM, Li FY: [Expression of bcl-10 protein in MALT lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2005 Dec;34(12):780-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of bcl-10 protein in MALT lymphoma].
  • OBJECTIVE: To investigate the significance of bcl-10 protein expression in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma.
  • METHODS: Sixty-two cases of MALT lymphoma were reviewed and immunohistochemical studies for bcl-10 and Ki-67 were performed.
  • There was no statistically significant correlation between bcl-10 nuclear expression and clinical tumor stage (P > 0.05) or tumor cell morphology (P > 0.05).
  • Amongst the 40 cases of gastrointestinal MALT lymphoma, bcl-10 nuclear expression correlated with extent of tumor involvement.
  • The protein was expressed in 36.4% (4 out of 11 cases) of MALT lymphoma confined to mucosa or submucosa, 65.2% (15 out of 23 cases) of those invading down to muscularis propria or subserosa, and 100% (all 6 cases) of those extending beyond serosa (P < 0.05).
  • CONCLUSIONS: Two expression patterns of bcl-10 protein were observed in MALT lymphoma: mixed nuclear-cytoplasmic and cytoplasmic only.
  • Immunohistochemical detection of bcl-10 may carry some diagnostic and prognostic implications in assessment of MALT lymphoma.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Lymphoma, B-Cell, Marginal Zone / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Age Factors. Aged. Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Hashimoto Disease / metabolism. Humans. Intestinal Neoplasms / metabolism. Intestinal Neoplasms / pathology. Ki-67 Antigen / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Middle Aged. Neoplasm Invasiveness. Sex Factors. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545185.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BCL10 protein, human; 0 / Ki-67 Antigen
  •  go-up   go-down


66. Tse KW, Dang-Lawson M, Lee RL, Vong D, Bulic A, Buckbinder L, Gold MR: B cell receptor-induced phosphorylation of Pyk2 and focal adhesion kinase involves integrins and the Rap GTPases and is required for B cell spreading. J Biol Chem; 2009 Aug 21;284(34):22865-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B cell receptor-induced phosphorylation of Pyk2 and focal adhesion kinase involves integrins and the Rap GTPases and is required for B cell spreading.
  • Signaling by the B cell receptor (BCR) promotes integrin-mediated adhesion and cytoskeletal reorganization.
  • This results in B cell spreading, which enhances the ability of B cells to bind antigens and become activated.
  • Proline-rich tyrosine kinase (Pyk2) and focal adhesion kinase (FAK) are related cytoplasmic tyrosine kinases that regulate cell adhesion, cell morphology, and cell migration.
  • Importantly B cell spreading induced by BCR/integrin co-stimulation or by integrin engagement was inhibited by short hairpin RNA-mediated knockdown of either Pyk2 or FAK expression and by treatment with PF-431396, a chemical inhibitor that blocks the kinase activities of both Pyk2 and FAK.
  • Thus Pyk2 and FAK are downstream targets of the Rap GTPases that play a key role in regulating B cell morphology.
  • [MeSH-major] B-Cell Activation Factor Receptor / physiology. B-Lymphocytes / metabolism. Focal Adhesion Kinase 1 / metabolism. Focal Adhesion Kinase 2 / metabolism. Integrins / physiology. rap GTP-Binding Proteins / physiology
  • [MeSH-minor] Actins / metabolism. Animals. Cell Line, Tumor. Cells, Cultured. Extracellular Matrix / metabolism. Fluorescent Antibody Technique. Immunoblotting. Mice. Mice, Inbred C57BL. Microscopy, Confocal. Phosphorylation. RNA, Small Interfering. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2639-44 [12604779.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3065-73 [12626562.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(7):2857-68 [16537926.001]
  • [Cites] Science. 2006 May 5;312(5774):738-41 [16675699.001]
  • [Cites] Science. 2006 Jun 16;312(5780):1672-6 [16778060.001]
  • [Cites] Eur J Immunol. 2006 Aug;36(8):2235-49 [16821235.001]
  • [Cites] Curr Biol. 2006 Sep 19;16(18):1796-806 [16979556.001]
  • [Cites] Immunity. 2006 Dec;25(6):989-1001 [17112751.001]
  • [Cites] Science. 2007 Jan 26;315(5811):528-31 [17185562.001]
  • [Cites] Immunity. 2007 May;26(5):655-67 [17509908.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10619-24 [17537919.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1723-32 [17568820.001]
  • [Cites] J Cell Biol. 2008 Jan 14;180(1):187-203 [18195107.001]
  • [Cites] Immunity. 2008 Jan;28(1):75-87 [18191594.001]
  • [Cites] Mol Cell Biol. 2008 Mar;28(5):1802-14 [18086875.001]
  • [Cites] Immunity. 2009 Feb 20;30(2):264-76 [19185517.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):11502-12 [12514172.001]
  • [Cites] Nat Immunol. 2003 Aug;4(8):741-8 [12845325.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36763-76 [12815062.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10740-5 [12960403.001]
  • [Cites] J Biol Chem. 2003 Oct 24;278(43):41756-67 [12904304.001]
  • [Cites] J Exp Med. 2003 Nov 17;198(10):1539-50 [14610042.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12009-19 [14701796.001]
  • [Cites] Immunology. 2004 Apr;111(4):400-6 [15056376.001]
  • [Cites] Immunity. 2004 May;20(5):589-99 [15142527.001]
  • [Cites] Mol Immunol. 2004 Jul;41(6-7):599-613 [15219998.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 5;1692(2-3):77-102 [15246681.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33315-22 [15166227.001]
  • [Cites] Dev Cell. 2004 Oct;7(4):585-95 [15469846.001]
  • [Cites] J Immunol Methods. 1983 Aug 12;62(1):31-7 [6875265.001]
  • [Cites] Growth Factors. 1989;2(1):73-82 [2699570.001]
  • [Cites] J Exp Med. 1991 Mar 1;173(3):599-607 [1997648.001]
  • [Cites] J Immunol. 1993 Mar 1;150(5):1645-52 [7679689.001]
  • [Cites] J Biol Chem. 1994 May 27;269(21):14869-71 [8195116.001]
  • [Cites] Methods Cell Biol. 1994;43 Pt A:99-112 [7823872.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Cell Signal. 2000 Mar;12(3):123-33 [10704819.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6074-83 [10913189.001]
  • [Cites] J Biol Chem. 2000 Aug 4;275(31):23409-12 [10801898.001]
  • [Cites] Nat Immunol. 2000 Jul;1(1):31-6 [10881171.001]
  • [Cites] FEBS Lett. 2001 Jun 1;498(1):26-31 [11389892.001]
  • [Cites] Eur J Immunol. 2001 May;31(5):1417-27 [11465098.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1086-94 [11493455.001]
  • [Cites] Nat Cell Biol. 2002 Apr;4(4):E65-8 [11944032.001]
  • [Cites] Nat Rev Immunol. 2002 May;2(5):354-63 [12033741.001]
  • [Cites] J Immunol. 2002 Aug 1;169(3):1365-71 [12133960.001]
  • [Cites] Leuk Lymphoma. 2002 Aug;43(8):1663-71 [12400610.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):945-56 [12461567.001]
  • [Cites] J Cell Biol. 2003 Jan 6;160(1):137-46 [12515828.001]
  • [Cites] J Exp Med. 2003 Feb 17;197(4):461-73 [12591904.001]
  • [Cites] Science. 1996 Apr 12;272(5259):263-7 [8602510.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1855-61 [8634433.001]
  • [Cites] J Biol Chem. 1997 Jan 3;272(1):228-32 [8995252.001]
  • [Cites] Immunology. 1997 Jan;90(1):147-53 [9038725.001]
  • [Cites] Immunity. 1997 Oct;7(4):549-57 [9354475.001]
  • [Cites] J Immunol. 1998 Jun 1;160(11):5366-73 [9605136.001]
  • [Cites] J Cell Sci. 1998 Jul 30;111 ( Pt 14):1981-91 [9645946.001]
  • [Cites] EMBO J. 1998 Oct 15;17(20):5933-47 [9774338.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):2338-50 [10022920.001]
  • [Cites] Nature. 1999 Aug 26;400(6747):891-4 [10476970.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):56-68 [15688067.001]
  • [Cites] Curr Opin Cell Biol. 2005 Apr;17(2):123-8 [15780587.001]
  • [Cites] Immunol Res. 2005;31(3):267-82 [15888917.001]
  • [Cites] J Biol Chem. 2005 Jun 3;280(22):21129-36 [15778498.001]
  • [Cites] Biol Chem. 2005 Sep;386(9):919-29 [16164417.001]
  • [Cites] Immunity. 2005 Nov;23(5):503-14 [16286018.001]
  • [Cites] J Immunol. 2005 Dec 15;175(12):8138-45 [16339552.001]
  • [Cites] EMBO J. 2006 Feb 22;25(4):889-99 [16456548.001]
  • (PMID = 19561089.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / B-Cell Activation Factor Receptor; 0 / Integrins; 0 / RNA, Small Interfering; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / Focal Adhesion Kinase 2; EC 2.7.10.2 / Ptk2 protein, mouse; EC 2.7.10.2 / Ptk2b protein, mouse; EC 3.6.5.2 / rap GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC2755694
  •  go-up   go-down


67. Reichard KK, McKenna RW, Kroft SH: ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol; 2007 Mar;20(3):310-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature.
  • We report detailed clinical and pathologic features of four cases of anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK-DLBCL), a rare entity with only 29 currently reported cases.
  • Biopsies from four adult patients aged 41, 49, 53, and 71 years (three lymph nodes and one nasopharyngeal mass) exhibited immunoblastic/plasmablastic morphology.
  • [MeSH-major] Lymphoma, B-Cell / enzymology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / enzymology. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277765.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


68. Ikenberg K, Springer E, Bräuninger W, Kerl K, Mihic D, Schmid S, Schmitt A, Yeginsoy S, Bode B, Weber A: Oropharyngeal lesions and cervical lymphadenopathy: syphilis is a differential diagnosis that is still relevant. J Clin Pathol; 2010 Aug;63(8):731-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Fine needle aspiration of enlarged cervical lymph nodes was evaluated by cytology and flow cytometry (fluorescence-activated cell sorting analysis), and biopsies were examined by using histology.
  • Co-existing oropharyngeal lesions should alert the physician to this differential diagnosis; and lesions with compatible morphology should be tested with immunohistochemistry and immunocytochemistry and/or molecular analysis to confirm the diagnosis of syphilis.
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. DNA, Bacterial / analysis. Diagnosis, Differential. Female. Humans. Lymph Nodes / pathology. Lymphoma / diagnosis. Male. Middle Aged. Neck. Polymerase Chain Reaction / methods. Tongue / pathology. Treponema pallidum / isolation & purification. Ultrasonography, Interventional / methods

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - Syphilis.
  • MedlinePlus Health Information. consumer health - Throat Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20702475.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Bacterial
  •  go-up   go-down


69. Khan AU, Sheikh MU, Intekhab K: Pre-existing malnutrition and treatment outcome in children with acute lymphoblastic leukaemia. J Pak Med Assoc; 2006 Apr;56(4):171-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred and sixty three patients with Acute Lymphoblastic Leukaemia (ALL) below the age of 14 years with L1 and L2 FAB morphology were included in this study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Malnutrition / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Malnutrition.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16711338.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


70. Laskov R, Berger N, Scharff MD, Horwitz MS: Tumor necrosis factor-alpha and CD40L modulate cell surface morphology and induce aggregation in Ramos Burkitt's lymphoma cells. Leuk Lymphoma; 2006 Mar;47(3):507-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor-alpha and CD40L modulate cell surface morphology and induce aggregation in Ramos Burkitt's lymphoma cells.
  • Interaction of CD40L and its cognate receptor is an essential component of B-lymphocyte signaling, affecting various aspects of B-cell differentiation pathways and immunoglobulin gene expression.
  • However, much less is known about the biological consequences of B-cell signaling through tumor necrosis factor (TNF)-alpha and its cognate receptors TNF-R1 and 2.
  • We used Ramos Burkitt's lymphoma cell line as a model system to study the direct effects of these cytokines on B cells.
  • Treatment of Ramos cells with either TNF-alpha or CD40L, but not with interleukin (IL)- 4, interferon (IFN)-gamma and transforming growth factor (TGF)-beta, resulted in enhanced cell aggregation and enhancement of adherence to glass cover-slips.
  • Scanning electron microscopy showed that Ramos cells have a polarized cell surface morphology and exhibit at least 3 cell surface morphological domains: microvilli, filopodia and ruffled membranes.
  • The cells adhered to the glass matrix through multiple filopodia/podopodia-like cell processes and demonstrated distinct ruffled-like membrane projections on their opposite pole.
  • [MeSH-major] Burkitt Lymphoma / immunology. Burkitt Lymphoma / pathology. CD40 Ligand / pharmacology. Cell Aggregation / drug effects. Cell Membrane / drug effects. Tumor Necrosis Factor-alpha / pharmacology
  • [MeSH-minor] Antigens, CD95. Cell Adhesion / drug effects. Cell Line, Tumor. Humans. Intercellular Adhesion Molecule-1 / drug effects. Intercellular Adhesion Molecule-1 / immunology. Receptors, Tumor Necrosis Factor / drug effects. Receptors, Tumor Necrosis Factor / immunology. Receptors, Tumor Necrosis Factor, Type I / biosynthesis. Receptors, Tumor Necrosis Factor, Type II / biosynthesis. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16523591.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / 1PO1 DK52956; United States / NIAID NIH HHS / AI / AI43937; United States / NCI NIH HHS / CA / CA72649
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / FAS protein, human; 0 / Receptors, Tumor Necrosis Factor; 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Receptors, Tumor Necrosis Factor, Type II; 0 / Tumor Necrosis Factor-alpha; 126547-89-5 / Intercellular Adhesion Molecule-1; 147205-72-9 / CD40 Ligand
  •  go-up   go-down


71. Attygalle AD, Chuang SS, Diss TC, Du MQ, Isaacson PG, Dogan A: Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology; 2007 Mar;50(4):498-508
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics.
  • AIMS: To identify distinguishing histological, immunophenotypic and molecular genetic features between angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma (PTL).
  • METHODS: Nodal T-cell lymphomas examined (n =137), included AITL (n = 89), PTL (n = 22), anaplastic large cell lymphoma (n = 16) and 'AITL/PTL indeterminate' (n = 10) with overlapping features between AITL and PTL, showing morphology typical of AITL but lacking follicular dendritic cell expansion.
  • Immunohistochemistry for CD3, CD20, CD21 and CD10, in situ hybridization for Epstein-Barr virus encoded RNA (EBER) and polymerase chain reaction for T-cell and B-cell clonality analysis were performed.
  • RESULTS: Of the AITLs, 74/89 showed typical morphology, whereas 15/89 showed hyperplastic follicles.
  • Detection of T-cell clonality was significantly higher in AITL (90%) compared with PTLu (59%).
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis
  • [MeSH-minor] Antigens, CD20 / metabolism. Antigens, CD3 / metabolism. B-Lymphocytes / pathology. Clone Cells. Diagnosis, Differential. Gene Rearrangement. Herpesvirus 4, Human / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Immunophenotyping. Neprilysin / metabolism. Polymerase Chain Reaction. RNA, Viral / analysis. Receptors, Antigen, T-Cell, gamma-delta / genetics. Receptors, Complement 3d / metabolism. Sensitivity and Specificity. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448026.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Immunoglobulin Heavy Chains; 0 / RNA, Viral; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


72. Basu D, Siddaraju N, Murugan P, Badhe BA, Akkarappatty C, Dutta TK: Cytologic aspects of T-cell acute lymphoblastic leukemia presenting as a massive pericardial effusion: a case report. Acta Cytol; 2009 May-Jun;53(3):337-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic aspects of T-cell acute lymphoblastic leukemia presenting as a massive pericardial effusion: a case report.
  • However, a careful examination of May-Grünwald-Giemsa-stained cytologic smears, under an oil immersion objective (x 1,000), showed atypical lymphoid cells having blastoid morphology.
  • A hematologic workup was carried out to exclude leukemia/lymphoma.
  • A diagnosis of T-cell acute lymphoblastic leukemia (FAB L1) was offered, and the patient was started on a remission and induction regimen.
  • [MeSH-major] Cardiac Tamponade / pathology. Pericardial Effusion / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19534280.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Biomarkers, Tumor; EC 2.7.7.31 / DNA Nucleotidylexotransferase
  •  go-up   go-down


73. Chen YH, Tang YM, Shen HQ, Song H, Yang SL, Shi SW, Qian BQ, Xu WQ, Ning BT: [Targeted killing of the Nalm-6 cells with 2E8-Genistein immunotoxin and its mechanism]. Zhonghua Er Ke Za Zhi; 2009 Jan;47(1):57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although chemotherapy is very effective in terms of cell killing, severe side effects such as severe infections, intracranial hemorrhage etc. are frequently encountered due to its poor selective damage between normal and malignant cells or tissues.
  • The aim of this study was to investigate the targeting efficacy in vitro with a new clone of anti-human CD19 antibody immunotoxin 2E8-Genistein on B lineage leukemia cell line Nalm-6 cells and its mechanisms in order to provide the evidence of target therapy on B lineage leukemia and lymphoma.
  • Nalm-6, a CD19+ B cell leukemia cell line, was used as target cells, while Molt-3, a CD19-T cell leukemia cell line, was taken as the negative control.
  • The morphology of the cells was observed under the reverted reversed light microscope and the viability was checked with either trypan blue exclusion or MTT methods.
  • Two-color flow cytometry was applied to study the mechanism of cell killing.
  • RESULTS: After 24 hours of culture, 2E8-Genistein showed marked target killing on Nalm-6 cells at nine different concentrations from 20 nmol/L through 100 nmol/L with cell survival rates from (71.8 +/- 7.9)% down to (16.6 +/- 12.9)%, respectively (n = 3), which were all significantly lower than that of control group (100 +/- 13.9)% (P < 0.05).
  • Significant difference was observed between the cell growth curve of Nalm-6 cultured with 100 nmol/L of 2E8-Gen and those of Nalm-6 cultured with medium (blank), PBS (negative control) or the same concentration of pure 2E8 antibody (negative control) groups (F = 152.15, P = 2.15 x 10(-7)), but there was no significant difference among the three control groups (F = 1.51, P = 0.29).
  • When Molt-3 cells were used as target cells, the cell growth curves of Molt-3 cultured with 2E8-Gen (100 nmol/L) and with negative control of blank did not show any significant difference (F = 0.34, P = 0.59).
  • [MeSH-minor] Antigens, CD19. Apoptosis / drug effects. Cell Line, Tumor. Flow Cytometry. Humans. Leukemia, B-Cell / immunology

  • Hazardous Substances Data Bank. GENISTEIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19573385.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD19; 0 / Immunotoxins; DH2M523P0H / Genistein
  •  go-up   go-down


74. Chang CC, Zhou X, Taylor JJ, Huang WT, Ren X, Monzon F, Feng Y, Rao PH, Lu XY, Fabio F, Hilsenbeck S, Creighton CJ, Jaffe ES, Lau CC: Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol; 2009 Nov 12;2:47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma.
  • BACKGROUND: Plasmablastic lymphoma (PL) is a subtype of diffuse large B-cell lymphoma (DLBCL).
  • Studies have suggested that tumors with PL morphology represent a group of neoplasms with clinopathologic characteristics corresponding to different entities including extramedullary plasmablastic tumors associated with plasma cell myeloma (PCM).
  • There were some segmental gains and some segmental loss that occurred in PL but not in the other types of lymphoma suggesting that these foci may contain genes responsible for the differentiation of this lymphoma.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Cancer. 2004 Aug 7;4:45 [15298715.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):299-303 [14981516.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Sep 1;16(1):1-9 [9377118.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2477-85 [16317097.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):313-25 [16616336.001]
  • [Cites] Neoplasia. 2008 Jan;10(1):89-98 [18231642.001]
  • [Cites] Mod Pathol. 2008 May;21(5):599-608 [18246049.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):281-91 [18398573.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] FEBS Lett. 2000 Jan 28;466(2-3):367-71 [10682862.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):e15 [11842121.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]
  • [Cites] J Hepatol. 2003 Mar;38(3):298-306 [12586295.001]
  • [Cites] Clin Lymphoma. 2003 Sep;4(2):86-92 [14556679.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • (PMID = 19909553.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] ENG
  • [Grant] United States / NLM NIH HHS / LM / R01 LM010185; United States / NIDCR NIH HHS / DE / DE017086
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2789747
  •  go-up   go-down


75. Hedvat CV, Teruya-Feldstein J, Puig P, Capodieci P, Dudas M, Pica N, Qin J, Cordon-Cardo C, Di Como CJ: Expression of p63 in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol; 2005 Sep;13(3):237-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p63 in diffuse large B-cell lymphoma.
  • The p63 gene, a homolog of the tumor suppressor gene TP53, maps to chromosome 3q27-28, a region frequently displaying genomic amplification in squamous cell carcinomas. p63 is expressed in a variety of epithelial tissues and has been reported to be critical for the normal development of stratified epithelia, including skin epidermis.
  • In a previous study, the authors reported the expression of p63 in occasional cells in the germinal center of lymph nodes and also observed p63 expression in B-cell lymphomas, among other tumor types surveyed in that analysis.
  • The present study was conducted to further analyze the potential clinical significance of identifying p63 expression, assessing a larger cohort of well-characterized patients with diffuse large B-cell lymphoma (DLBCL) (n = 172 cases) and a panel of established lymphoma cell lines. p63 expression at the microanatomic detail was examined by immunohistochemistry using a monoclonal antibody (clone 4A4), while distinction of p63 isoforms was analyzed by Western blotting and reverse transcription-polymerase chain reaction using isoform-specific primers.
  • Examination of the different p63 isoforms revealed that the DeltaNp63 species was expressed by only one cell line, while the other p63 isoforms were found in most cell lines analyzed.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16082248.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-47179; United States / NCI NIH HHS / CA / CA-87497; United States / NIDDK NIH HHS / DK / DK-47650; United States / NHLBI NIH HHS / HL / HL-04478
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / Protein Isoforms; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


76. Kost CB, Holden JT, Mann KP: Marginal zone B-cell lymphoma: a retrospective immunophenotypic analysis. Cytometry B Clin Cytom; 2008 Sep;74(5):282-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marginal zone B-cell lymphoma: a retrospective immunophenotypic analysis.
  • BACKGROUND: Marginal zone B-cell lymphoma (MZL) comprises three related yet biologically distinct subtypes--splenic MZL (SMZL), nodal MZL (NMZL), and extranodal MZL of MALT type (MALT).
  • In cases without adequate morphology, immunophenotypic characterization by flow cytometric immunophenotyping (FCI) relies heavily on exclusion of other low-grade lymphomas.
  • We compared these to follicular lymphoma (FL) as we were specifically interested in differentiating MZL from CD10 negative FL.
  • CONCLUSIONS: MZL expresses typical pan-B-cell antigens.
  • [MeSH-major] Immunophenotyping / methods. Lymphoma, B-Cell, Marginal Zone / diagnosis
  • [MeSH-minor] Antibodies, Neoplasm / immunology. Antigens, Neoplasm / immunology. Fluorescence. Humans. Lymphoma, Follicular / immunology. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500740.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm
  •  go-up   go-down


77. Chouairy CJ, Salloum AN, Ghazal GY: Small cell neuroendocrine carcinoma of the urinary bladder: report on two cases and review of the literature. J Med Liban; 2010 Apr-Jun;58(2):111-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell neuroendocrine carcinoma of the urinary bladder: report on two cases and review of the literature.
  • Small cell (Neuroendocrine) carcinoma of the urinary bladder is a rare but highly aggressive malignancy.
  • It is morphologically indistinguishable from the more common pulmonary small cell carcinoma.
  • It can occur either in association with urothelial (transitional cell) carcinoma or in a pure form.
  • Histologically, it can mimic poorly differentiated urothelial carcinoma and lymphoma.
  • In this article, we report on two cases occurring in a pure form and we briefly review the published literature regarding the clinical presentation, morphology, differential diagnosis, prognosis and treatment.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20549899.001).
  • [ISSN] 0023-9852
  • [Journal-full-title] Le Journal médical libanais. The Lebanese medical journal
  • [ISO-abbreviation] J Med Liban
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Lebanon
  • [Number-of-references] 41
  •  go-up   go-down


78. Camara DA, Stefanoff CG, Pires AR, Soares F, Biasoli I, Zalcberg I, Spector N, Lopes VS, Morais JC: Immunoblastic morphology in diffuse large B-cell lymphoma is associated with a nongerminal center immunophenotypic profile. Leuk Lymphoma; 2007 May;48(5):892-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoblastic morphology in diffuse large B-cell lymphoma is associated with a nongerminal center immunophenotypic profile.
  • Diffuse large B cell lymphomas (DLCBL) are a group of lymphomas whose biologic and prognostic diversity has been recently well characterized.
  • There is also morphologic heterogeneity, but the relevance of subclassification remains uncertain.
  • The World Health Organization Classification states that pathologists have the choice to use only the term diffuse large B-cell lymphoma or to use one of the specific morphologic variants.
  • The aim of the present study was to evaluate if there is an association between immunoblastic morphology and the immunophenotypic profile in DLBCL.
  • Cases of immunoblastic lymphoma and cases of centroblastic polymorphic lymphoma with more than 50% immunoblasts were defined as having immunoblastic morphology.
  • Patients with immunoblastic morphology more frequently had a non-GCB phenotype (94% vs 6%).
  • This finding suggests that the morphological subclassification of DLBCL does have biological meaning, in line with recent evidence indicating that the immunoblastic morphology should not be overlooked in lymphoma classification.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Immunophenotyping / methods. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / chemistry. Cell Transformation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Phenotype. Prognosis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487732.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


79. Coffin CM, Hornick JL, Fletcher CD: Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol; 2007 Apr;31(4):509-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we report a subset of IMTs with histologic atypia and/or clinical aggressiveness that were analyzed for clinicopathologic features, outcome, and immunohistochemical expression of anaplastic lymphoma kinase (ALK) and other markers to identify potential pathologic prognostic features.
  • Fifty-nine IMTs with classic morphology (5 cases), atypical histologic features (21 cases), local recurrence (27 cases), and/or metastasis (6 cases) were studied.
  • Histologic evolution to a more pleomorphic cellular, spindled, polygonal, or round cell morphologic pattern was observed in 7 cases.
  • Other proliferative, apoptotic, and prognostic markers did not correlate well with morphology or outcome.


80. Hasserjian RP, Ott G, Elenitoba-Johnson KS, Balague-Ponz O, de Jong D, de Leval L: Commentary on the WHO classification of tumors of lymphoid tissues (2008): "Gray zone" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma. J Hematop; 2009 Jul;2(2):89-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Commentary on the WHO classification of tumors of lymphoid tissues (2008): "Gray zone" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma.
  • The 2008 WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues has introduced two new categories of high-grade B-cell lymphomas: entities in which features of diffuse large B-cell lymphoma (DLBCL) overlap with Burkitt lymphoma (DLBCL/BL) or classical Hodgkin lymphoma (DLBCL/HL).
  • The DLBCL/BL category encompasses cases that resemble Burkitt lymphoma morphologically, but have one or more immunophenotypic or molecular genetic deviations that would exclude it from the BL category; conversely, some cases have immunophenotypic and/or genetic features of BL, but display cytologic variability unacceptable for BL.
  • The DLBCL/HL category encompasses lymphomas that exhibit the morphology of classical Hodgkin lymphoma but the immunophenotype of DLBCL, or vice versa.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Nov 15;98(10):3082-6 [11698294.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1172-80 [12429796.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2756-61 [12446450.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1086-94 [16006805.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):489-95 [12478664.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):243-53 [12507907.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Blood. 2004 Jul 15;104(2):543-9 [15044251.001]
  • [Cites] Adv Anat Pathol. 2004 Sep;11(5):227-38 [15322489.001]
  • [Cites] Histopathology. 2004 Dec;45(6):619-24 [15569053.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2535-42 [15572583.001]
  • [Cites] Histopathology. 2005 Mar;46(3):241-55 [15720410.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1392-9 [15870177.001]
  • [Cites] Histopathology. 2005 Jul;47(1):101-10 [15982329.001]
  • [Cites] Genes Chromosomes Cancer. 1990 Jul;2(2):147-58 [2278969.001]
  • [Cites] Histopathology. 1986 Apr;10(4):379-90 [2423430.001]
  • [Cites] Leukemia. 2009 Feb;23(2):225-34 [18923440.001]
  • [Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Leukemia. 2007 Dec;21(12):2463-9 [17728785.001]
  • [Cites] Leukemia. 2007 Apr;21(4):780-7 [17375124.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):106-12 [17197926.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4135-42 [16943530.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2679-84 [16532038.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):25-33 [16258503.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1411-21 [16224207.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):730-9 [2788371.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):1893-8 [3167803.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1571-8 [8608249.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):877-88 [8669537.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1159-63 [8683996.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S31-8 [9926235.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1558-67 [10334544.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):123-33 [10337996.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):846-52 [10843287.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1277-82 [11688462.001]
  • (PMID = 19669187.001).
  • [ISSN] 1868-9256
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


81. Hunt KE, Hall B, Reichard KK: Translocations involving MUM1 are rare in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol; 2010 Mar;18(2):109-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocations involving MUM1 are rare in diffuse large B-cell lymphoma.
  • Diffuse large B-cell lymphoma (DLBCL) comprises a diverse group of neoplasms that have recently been subdivided by gene expression profiling and immunohistochemical studies into at least 2 subgroups [germinal center (GC) type and non-GC type].
  • We hypothesized that MUM1 may be dysregulated/up-regulated in these tumors by a chromosomal translocation, as is seen in many cases of plasma cell myeloma [where MUM1 is juxtaposed with the immunoglobulin heavy chain gene (IgH)].

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18815567.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4
  •  go-up   go-down


82. Ongaro A, De Mattei M, Della Porta MG, Rigolin G, Ambrosio C, Di Raimondo F, Pellati A, Masieri FF, Caruso A, Catozzi L, Gemmati D: Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica; 2009 Oct;94(10):1391-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Folic Acid / metabolism. Methotrexate / adverse effects. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Tetrahydrofolate Dehydrogenase / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827859209 for PMID:19648163 [PharmGKB] .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2007 May 15;109(10):4151-7 [17264302.001]
  • [Cites] Am J Clin Nutr. 2007 Apr;85(4):1098-102 [17413111.001]
  • [Cites] Ann Hematol. 2007 Aug;86(8):609-11 [17323057.001]
  • [Cites] Leuk Res. 2007 Dec;31(12):1669-74 [17512587.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3692-700 [18096764.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 May;30(5):347-52 [18458567.001]
  • [Cites] Pharmacogenet Genomics. 2008 Jul;18(7):577-89 [18551038.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1798-800 [18368069.001]
  • [Cites] Am J Hematol. 2009 Aug;84(8):526-9 [19536847.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Mol Genet Metab. 2000 Aug;70(4):310-5 [10993718.001]
  • [Cites] Haematologica. 2001 Feb;86(2):121-7 [11224479.001]
  • [Cites] Blood. 2001 Jul 1;98(1):231-4 [11418485.001]
  • [Cites] Arthritis Rheum. 2001 Nov;44(11):2525-30 [11710708.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1033-4 [11937185.001]
  • [Cites] Rheumatology (Oxford). 2002 Jun;41(6):658-65 [12048292.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2055-61 [12357357.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3832-4 [12411325.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:162-92 [12446423.001]
  • [Cites] Ann Oncol. 2002 Dec;13(12):1915-8 [12453860.001]
  • [Cites] Am J Med Genet A. 2004 Feb 1;124A(4):339-45 [14735580.001]
  • [Cites] Pharmacogenomics J. 2004;4(1):66-72 [14647408.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):787-94 [15159311.001]
  • [Cites] Pharmacogenomics. 2004 Oct;5(7):819-34 [15469405.001]
  • [Cites] J Biol Chem. 1984 Mar 25;259(6):3933-43 [6323448.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):5879-83 [2790801.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):828-35 [1988122.001]
  • [Cites] Nat Genet. 1995 May;10(1):111-3 [7647779.001]
  • [Cites] Cell Struct Funct. 1995 Jun;20(3):191-7 [7586009.001]
  • [Cites] Mol Genet Metab. 1998 Jul;64(3):169-72 [9719624.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):110-7 [15630450.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2482-7 [15781665.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Pharmacogenomics J. 2005;5(6):374-80 [16130010.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1113-6 [16870553.001]
  • [Cites] J Hum Genet. 2007;52(2):166-71 [17180579.001]
  • [Cites] Haematologica. 2007 Mar;92(3):342-8 [17339183.001]
  • [Cites] Haematologica. 2007 Apr;92(4):478-85 [17488658.001]
  • (PMID = 19648163.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 1.5.1.3 / Tetrahydrofolate Dehydrogenase; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2754955
  •  go-up   go-down


83. Maeda M, Fukunaga Y, Asano T, Migita M, Ueda T, Hamada H, Hayakawa J, Narazaki H, Kaizu K: Clinical aspects of infant leukemia--experiences of a single institution of Japan: high level of serum immunoglobulin M in infant leukemia. J Nippon Med Sch; 2005 Dec;72(6):355-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient showing M7 morphology had Down syndrome.
  • Five ALL patients showed a B-cell precursor immunophenotype.
  • [MeSH-major] Immunoglobulin M / blood. Leukemia, Myeloid, Acute / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16415515.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin M; 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


84. Bacon CM, Diss TC, Ye H, Liu H, Goatly A, Hamoudi R, Wotherspoon A, Gascoyne RD, Dogan A, Du MQ, Isaacson PG: Follicular lymphoma of the thyroid gland. Am J Surg Pathol; 2009 Jan;33(1):22-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular lymphoma of the thyroid gland.
  • The majority of lymphomas arising in the thyroid gland are mucosa-associated lymphoid tissue lymphomas and diffuse large B-cell lymphomas, which arise from a background of chronic lymphocytic thyroiditis.
  • Follicular lymphoma may also present in the thyroid gland, but its clinicopathologic features at this site are not well characterized, leading to difficulties in diagnosis and clinical management.
  • We have addressed this problem by studying the clinical, morphologic, immunophenotypic, and genetic features of 22 such cases.
  • All cases showed morphology characteristic of follicular lymphoma, however, in many the interfollicular neoplastic infiltrate was particularly prominent and all lymphomas contained readily identifiable and often striking lymphoepithelial lesions, features heretofore considered indicative of mucosa-associated lymphoid tissue lymphoma at this site.
  • In 1 group, similar to typical adult follicular lymphoma, cases carried a t(14;18)/IGH-BCL2 and/or expressed Bcl-2, and were mostly CD10-positive and of World Health Organization (WHO) grade 1 to 2.
  • Appreciation of the spectrum of morphologic, immunophenotypic, and genetic characteristics of follicular lymphoma presenting in the thyroid gland should aid both diagnosis and clinical management.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Immunol. 2008 Jan;29(1):25-33 [18061541.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1254 [10561186.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):623-39 [10800981.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):846-52 [10843287.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3922-8 [10845929.001]
  • [Cites] Histopathology. 2000 Jul;37(1):10-8 [10931213.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):629-35 [11241227.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):105-11 [11788631.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):216-24 [11812943.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):647-55 [11821444.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2309-17 [12399977.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):614-7 [12461620.001]
  • [Cites] Int J Surg Pathol. 2001 Oct;9(4):287-93 [12574844.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2335-9 [12406890.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2489-95 [12456507.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):623-9 [12649111.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1012-8 [12676782.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Histopathology. 2004 Mar;44(3):268-76 [14987231.001]
  • [Cites] Curr Treat Options Oncol. 2004 Aug;5(4):307-13 [15233907.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):644-53 [15286744.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1722-6 [15356642.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Histopathology. 1978 May;2(3):201-13 [580930.001]
  • [Cites] Cancer. 1979 Aug;44(2):529-42 [383257.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1979 Aug 23;383(3):293-317 [158873.001]
  • [Cites] Am J Clin Pathol. 1980 Jul;74(1):1-11 [7395811.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]
  • [Cites] N Engl J Med. 1985 Mar 7;312(10):601-4 [3838363.001]
  • [Cites] Histopathology. 1985 Jan;9(1):81-97 [3884481.001]
  • [Cites] Cancer. 1986 Jul 1;58(1):100-4 [3708539.001]
  • [Cites] Hum Pathol. 1988 Nov;19(11):1315-26 [3141260.001]
  • [Cites] Blood. 1991 Aug 1;78(3):581-5 [1859876.001]
  • [Cites] Eur J Cancer. 1991;27(10):1201-8 [1835586.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):929-33 [1555984.001]
  • [Cites] Am J Pathol. 1992 Jul;141(1):43-52 [1632470.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6770-4 [1495966.001]
  • [Cites] J Exp Med. 1992 Oct 1;176(4):1137-48 [1402658.001]
  • [Cites] Histopathology. 1994 Apr;24(4):323-7 [8045521.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):140-7 [7799014.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] Histopathology. 1996 Jan;28(1):25-32 [8838117.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4708-14 [9616169.001]
  • [Cites] Mod Pathol. 1998 Sep;11(9):864-9 [9758366.001]
  • [Cites] Cell. 1999 Jan 8;96(1):35-45 [9989495.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1626-35 [10193956.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3601-9 [10339464.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):316-23 [10375088.001]
  • [Cites] Am J Clin Pathol. 1999 Aug;112(2):263-70 [10439808.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):69-82 [15613857.001]
  • [Cites] J Pathol. 2005 Feb;205(3):329-35 [15682435.001]
  • [Cites] J Pathol. 2005 Feb;205(3):293-301 [15682443.001]
  • [Cites] Best Pract Res Clin Haematol. 2005 Mar;18(1):1-10 [15694181.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):73-8 [15735858.001]
  • [Cites] Leukemia. 2005 Apr;19(4):652-8 [15703784.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1058-63 [15815725.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6358-63 [16155020.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):529-36 [16625101.001]
  • [Cites] Histopathology. 2006 Sep;49(3):229-41 [16918969.001]
  • [Cites] Histopathology. 2006 Oct;49(4):426-9 [16978207.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):170-84 [17255761.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3076-9 [17138820.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):1050-8 [17592272.001]
  • (PMID = 18830125.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097274-069001; United States / NCI NIH HHS / CA / P50 CA097274-079001; United States / NCI NIH HHS / CA / CA097274-069001; United States / NCI NIH HHS / CA / CA097274-079001; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS80966; NLM/ PMC2673478
  •  go-up   go-down


85. Haque S, van Kirk R: Three patients with both Hodgkin's lymphoma and Castleman's disease: Clinicopathologic correlations and lack of association with HHV-8. Indian J Med Paediatr Oncol; 2009 Apr;30(2):76-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three patients with both Hodgkin's lymphoma and Castleman's disease: Clinicopathologic correlations and lack of association with HHV-8.
  • BACKGROUND: The relationship between Hodgkin's lymphoma (HL) and plasma cell-type Castleman's disease (PCD) has been well documented.
  • It predisposes patients to a much higher risk of other malignancies, including Kaposi's sarcoma and non-Hodgkin's lymphoma.
  • Cases linked to HHV-8 are associated with a different morphology than cases that are not linked to HHV-8.
  • It has been proposed that patients with both HL and CD will have lymph nodes with HHV-8-negative morphology.
  • All three cases had architectural features consistent with an HHV-8-negative morphology.
  • CONCLUSION: All three of our patients with both HL and CD had HHV-8-negative lymph node morphology and absence of HHV-8 by immunohistochemistry.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1991 Mar;18(3):249-53 [1675190.001]
  • [Cites] Am J Pathol. 1992 Jul;141(1):129-38 [1632458.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2923-30 [1954381.001]
  • [Cites] Arch Pathol Lab Med. 1994 Mar;118(3):270-4 [8135630.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):833-9 [8375854.001]
  • [Cites] Arch Pathol Lab Med. 1996 Jan;120(1):91-6 [8554455.001]
  • [Cites] J Virol. 1997 Jan;71(1):839-42 [8985427.001]
  • [Cites] Head Neck. 2001 Feb;23(2):166-9 [11303634.001]
  • [Cites] J Clin Pathol. 2001 Oct;54(10):790-1 [11577129.001]
  • [Cites] Am J Hematol. 2002 Feb;69(2):119-26 [11835348.001]
  • [Cites] Cancer. 1956 Jul-Aug;9(4):822-30 [13356266.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):91-100 [12502931.001]
  • [Cites] Histopathology. 2006 Feb;48(3):317-9 [16430484.001]
  • (PMID = 20596307.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2885879
  • [Keywords] NOTNLM ; Castleman's disease / HHV-8 / Hodgkin's lymphoma / plasma cell variant of Castleman's disease
  •  go-up   go-down


86. Bruna J, Martínez-Yelamos S, Alonso E, Romagosa V, Arruga J, Arruga J, Domingo A, Rojas-Marcos I, Petit J, Rubio F: Meningeal lymphomatosis as the first manifestation of splenic marginal zone lymphoma. Int J Hematol; 2005 Jul;82(1):63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal lymphomatosis as the first manifestation of splenic marginal zone lymphoma.
  • Meningeal lymphomatosis (ML) as the first manifestation of a splenic marginal zone lymphoma (SMZL) is rare.
  • The hemogram showed a predominance of lymphocytes with a villous morphology.
  • In this report, we discuss the other 2 cases and ML in B-cell chronic lymphoproliferative disorders.
  • [MeSH-major] Lymphoma / complications. Lymphoproliferative Disorders / etiology. Meninges / pathology. Splenic Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Neurol. 1983;22(4):289-92 [6884398.001]
  • [Cites] Leuk Lymphoma. 2002 Jun;43(6):1337-40 [12153005.001]
  • [Cites] Blood. 1993 May 15;81(10):2679-87 [7683926.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):104-15 [12672282.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2464-72 [12446449.001]
  • [Cites] Clin Lymphoma. 2002 Sep;3(2):117-20 [12435285.001]
  • [Cites] Curr Opin Neurol. 2002 Dec;15(6):691-9 [12447107.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):1819-38 [8669469.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):199-201 [11908730.001]
  • [Cites] Arch Pathol Lab Med. 1997 May;121(5):524-7 [9167611.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):731-6 [8652403.001]
  • [Cites] Cancer. 1994 Jul 1;74(1):61-5 [8004584.001]
  • [Cites] Blood. 2000 Jul 15;96(2):776-7 [10950515.001]
  • [Cites] Cancer Pract. 1998 Jul-Aug;6(4):223-8 [9767335.001]
  • [Cites] Acta Neurol Scand. 1979 Dec;60(6):363-70 [297427.001]
  • [Cites] Klin Wochenschr. 1985 May 2;63(9):423-7 [3999626.001]
  • [Cites] Leukemia. 1997 Mar;11(3):408-15 [9067581.001]
  • [Cites] Nouv Rev Fr Hematol. 1987;29(4):247-9 [3697064.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):148-54 [10319383.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jul;59(7):561-74 [10901227.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1648-54 [12176884.001]
  • [Cites] Acta Haematol. 1995;93(2-4):101-4 [7639049.001]
  • [Cites] Nervenarzt. 1999 Apr;70(4):363-7 [10355001.001]
  • [Cites] J Formos Med Assoc. 2000 Oct;99(10):775-8 [11061073.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1085-7 [6547873.001]
  • (PMID = 16105762.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antigens, CD
  •  go-up   go-down


87. Isaacson PG, Du MQ: Gastrointestinal lymphoma: where morphology meets molecular biology. J Pathol; 2005 Jan;205(2):255-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal lymphoma: where morphology meets molecular biology.
  • Primary gastrointestinal lymphomas are best exemplified by mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach and enteropathy-type T-cell lymphoma (ETL).
  • Here, the histopathology and recent advances in phenotypic and molecular characterization of gastric MALT lymphoma and ETL and their applications in diagnosis and clinical management are reviewed.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Chromosome Aberrations. Diagnosis, Differential. Humans. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / pathology. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15643667.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 130
  •  go-up   go-down


88. Gujral S, Polampalli S, Badrinath Y, Kumar A, Subramanian PG, Nair R, Sengar M, Nair C: Immunophenotyping of mature T/NK cell neoplasm presenting as leukemia. Indian J Cancer; 2010 Apr-Jun;47(2):189-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotyping of mature T/NK cell neoplasm presenting as leukemia.
  • INTRODUCTION: Mature T/NK cell lymphomas (MTNKL) presenting as leukemia are rare and show considerable overlapping of clinical, morphological and immunophenotypic features.
  • AIM: Critical analysis of the morphology and immunophenotypic profile of MTNKL.
  • MATERIALS AND METHODS: We reviewed 380 consecutive cases of mature lymphoid neoplasm that presented as leukemia and were diagnosed on morphology and immunophenotyping of bone marrow and/or peripheral blood samples.
  • It included four cases of T-large granular leukemia (T-LGL), two of T-cell prolymphocytic leukemia small cell variant (T-PLL), two of adult T-cell leukemia/lymphoma (ATLL) and one of primary cutaneous gamma delta T-cell lymphoma (PCGDTCL).
  • One case of T- PLL small cell variant showed CD4+/CD8- phenotype, while the other revealed CD4-/CD8+ phenotype.
  • CONCLUSION: Mature nodal T/NK cell neoplasms are rare and MTNKL presenting as leukemia are even rarer.
  • There is an overlap between the immunophenotypic profiles of different MTNKL subtypes and elaborate T/NK cell panels are required for their evaluation.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia, Prolymphocytic, T-Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, T-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20448385.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


89. Wimmer-Kleikamp SH, Nievergall E, Gegenbauer K, Adikari S, Mansour M, Yeadon T, Boyd AW, Patani NR, Lackmann M: Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells. Blood; 2008 Aug 1;112(3):721-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Signaling by Eph receptors and cell-surface ephrin ligands modulates adhesive cell properties and thereby coordinates cell movement and positioning in normal and oncogenic development.
  • While cell contact-dependent Eph activation frequently leads to cell-cell repulsion, also the diametrically opposite response, cell-cell adhesion, is a probable outcome.
  • We have examined cell-biologic mechanisms underlying this switch by analyzing ephrin-A5-induced cell-morphologic changes of EphA3-positive LK63 pre-B acute lymphoblastic leukemia cells.
  • Their exposure to ephrin-A5 surfaces leads to a rapid conversion from a suspended/nonpolarized to an adherent/polarized cell type, a transition that relies on EphA3 functions operating in the absence of Eph-kinase signaling.
  • Cell morphology change and adhesion of LK63 cells are effectively attenuated by endogenous protein tyrosine phosphatase (PTP) activity, whereby PTP inhibition and productive EphA3-phosphotyrosine signaling reverse the phenotype to nonadherent cells with a condensed cytoskeleton.
  • [MeSH-major] Cell Adhesion. Ephrins / physiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Protein Tyrosine Phosphatases / metabolism. Receptors, Eph Family / physiology
  • [MeSH-minor] Cell Line. Cell Line, Tumor. Cell Polarity. Cell Shape. Ephrin-A5 / physiology. Humans. Phosphorylation. Receptor, EphA3 / physiology. Signal Transduction

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2008 Aug 1;112(3):455-6 [18650455.001]
  • (PMID = 18385452.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ephrin-A5; 0 / Ephrins; EC 2.7.10.1 / Receptor, EphA3; EC 2.7.10.1 / Receptors, Eph Family; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


90. Ishii H, Joshita T, Matsuyama N, Uchida T, Ishikawa A, Ebihara Y: Immunohistochemical and ultrastructural investigation on cutaneous neuroendocrine carcinoma: report of a case and review of the literature. Med Mol Morphol; 2006 Sep;39(3):164-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a tumor in an 80-year-old man that was difficult to distinguish from other tumors, i.e., small cell carcinoma of the lung, PNET/Ewing tumor, malignant lymphoma, or malignant melanoma (amelanotic), and which was finally identified as cutaneous neuroendocrine carcinoma using immunohistochemical and ultrastructural methods.
  • Autopsy did not show any tumors in the lungs, excluding the possibility of small cell carcinoma of the lung.
  • Immunohistochemistry tests gave negative results for LCA, UCHL-1, CD3, and CD20, thereby excluding malignant lymphoma, and the negative results for S-100 protein and HMB-45 ruled out malignant melanoma.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1992 May;20(5):437-9 [1587495.001]
  • [Cites] Am J Dermatopathol. 1982 Dec;4(6):497-500 [7165057.001]
  • [Cites] Am J Dermatopathol. 1999 Feb;21(1):16-20 [10027519.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):5 [15611999.001]
  • [Cites] Dermatol Surg. 2000 Sep;26(9):853-6 [10971559.001]
  • [Cites] Am J Ophthalmol. 1992 Jun 15;113(6):674-80 [1598958.001]
  • [Cites] J Clin Pathol. 2001 Sep;54(9):727-9 [11533085.001]
  • [Cites] Am J Dermatopathol. 1996 Jun;18(3):273-7 [8806961.001]
  • [Cites] J Am Acad Dermatol. 1997 Nov;37(5 Pt 1):734-9 [9366819.001]
  • [Cites] Ann Surg. 1999 Jan;229(1):97-105 [9923806.001]
  • [Cites] Arch Dermatol. 1972 Jan;105(1):107-10 [5009611.001]
  • [Cites] Handchir Mikrochir Plast Chir. 1996 Jan;28(1):43-5 [8852641.001]
  • [Cites] Am J Clin Oncol. 2004 Dec;27(6):576-83 [15577435.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2002 Jan;16(1):82-3 [11952300.001]
  • [Cites] Ultrastruct Pathol. 2005 May-Aug;29(3-4):287-94 [16036883.001]
  • [Cites] J Cutan Pathol. 1986 Oct;13(5):347-58 [2946733.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):1-4 [15611998.001]
  • (PMID = 16998628.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


91. Pazur M, Jelić-Puskarić B, Planinc-Peraica A, Vrhovac R, Kardum-Skelin I, Jaksić B: T lymphoblastic leukaemia with an unusual Burkitt lymphoma morphology--a case report. Coll Antropol; 2010 Jun;34(2):675-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T lymphoblastic leukaemia with an unusual Burkitt lymphoma morphology--a case report.
  • Precursor T-cell acute lymphoblastic leukaemia (T-ALL)/lymphoma (T-LBL) is a neoplasm with cytological features that include blast cells of medium size, high nuclear cytoplasmic ratio and inconspicuous nucleoli, which are usually TdT (Terminal Deoxynucleotidyl Transferase) positive and variably express T-cell markers.
  • Bone marrow aspiration revealed 87% and peripheral blood 41% of lymphoblasts with cytoplasmic vacuoles which suggested Burkitt lymphoma (BL) morphology.
  • This excluded Burkitt lymphoma and led to diagnosis of T-ALL.
  • The patient was submitted to two cycles of chemotherapy, autologous stem cell transplantation, and intrathecal chemotherapy, but he died after 10 months because of disease complications (lung aspergillosis and pleural effusion).
  • Our case report showed how morphology alone can be misleading and sometimes is not enough in diagnosing ALL.
  • Beside morphologic criteria, setting correct diagnosis depends on identification of immunophenotype by flow cytometry and cytogenetic-molecular abnormalities.
  • [MeSH-major] Burkitt Lymphoma / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Antigens, CD2 / analysis. Bone Marrow / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Fatal Outcome. Humans. Karyotyping. Lymphocytes / pathology. Male. Middle Aged

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698152.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antigens, CD2
  •  go-up   go-down


92. Flatland B, Fry MM, Newman SJ, Moore PF, Smith JR, Thomas WB, Casimir RH: Large anaplastic spinal B-cell lymphoma in a cat. Vet Clin Pathol; 2008 Dec;37(4):389-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large anaplastic spinal B-cell lymphoma in a cat.
  • A left axillary mass was identified, and the results of fine needle aspiration cytology indicated malignant round cell neoplasia of possible histiocytic origin.
  • The initial histologic diagnosis was anaplastic sarcoma, but immunohistochemical results indicated the cells were CD20+ and CD45R+ and CD3-, compatible with a diagnosis of B-cell lymphoma.
  • Clonality of the B-cell population could not be demonstrated using PCR testing for antigen receptor gene rearrangement.
  • To the authors' knowledge, this is the first reported case of a feline spinal anaplastic B-cell lymphoma exhibiting bi- and multinucleated cells.
  • The prognostic significance of this cell morphology and immunophenotype is unknown.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vet Clin Pathol. 2008 Dec;37(4):360-2 [19055569.001]
  • (PMID = 19055573.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Hassan R, Felisbino F, Stefanoff CG, Pires V, Klumb CE, Dobbin J, Seuánez HN, Renault IZ: Burkitt lymphoma/leukaemia transformed from a precursor B cell: clinical and molecular aspects. Eur J Haematol; 2008 Mar;80(3):265-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma/leukaemia transformed from a precursor B cell: clinical and molecular aspects.
  • Burkitt lymphoma/leukaemia (BL/L) is a heterogeneous disease with respect to epidemiological patterns and cell origin.
  • The occurrence of BL/L with an immature phenotype raises the question whether this phenotype might be a consequence of early B-cell transformation or, alternatively, a secondary feature of transformed, mature B cells.
  • Here we describe the case of a 4-yr-old child with BL/L and FAB L3 morphology, with phenotypic and genotypic characteristics of a CD10+ precursor B-cell acute lymphoid leukaemia (ALL) associated with t(8;14)(q24;q32).
  • Molecular analysis showed expression of RAG1 and RAG2 and an unmutated VDJCmu immunoglobulin rearrangement coinciding with a lack of AICDA expression, indicating an immature B-cell origin.
  • His clinical response suggested that FAB L3 ALL with MYC rearrangement and an aberrant precursor B-cell phenotype is clinically similar to BL/L.
  • This case also allowed us to refine the description of cellular and molecular variants of BL/L regarding the <